[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 460
1. Halldorsson A, Dissanaike S, Kaye KS: Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour. J Clin Pathol; 2005 Nov;58(11):1211-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour.
  • Alveolar adenomas are extremely rare, and are probably benign lung tumours of unknown histogenesis.
  • This report describes a case of alveolar adenoma in a 43 year old white man, who presented with pleuritic chest pain.
  • A chest x ray and computerised tomography scan demonstrated a solitary left lower lobe lung nodule.
  • Histologically, the lesion was well demarcated, dominated by large and small cysts with no normal lung parenchyma.
  • [MeSH-major] Adenoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):155-9 [15173924.001]
  • [Cites] Pathologe. 1990 Jan;11(1):48-54 [2179944.001]
  • [Cites] Pathologe. 1996 Mar;17(2):150-3 [8650145.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):34-7 [8689607.001]
  • [Cites] Virchows Arch. 1996 Oct;429(2-3):101-8 [8917711.001]
  • [Cites] Virchows Arch. 1997 Feb;430(2):181-4 [9083522.001]
  • [Cites] Pol J Pathol. 2003;54(2):147-52 [14575424.001]
  • [Cites] Cesk Patol. 1997 May;33(2):49-52 [9340215.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):158-67 [10029443.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):1066-71 [3759064.001]
  • [Cites] Ann Pathol. 1999 Sep;19(4):325-8 [10544770.001]
  • [Cites] J Thorac Imaging. 2002 Apr;17(2):163-6 [11956369.001]
  • [Cites] Rontgenpraxis. 1997 Feb;50(2):29-30 [9173555.001]
  • (PMID = 16254114.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770767
  •  go-up   go-down


2. Miyazaki M, Yamazaki H, Takeuchi H, Saoo K, Yokohira M, Masumura K, Nohmi T, Funae Y, Imaida K, Kamataki T: Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis; 2005 Nov;26(11):1947-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.
  • Recently we reported that the occurrence of lung adenoma caused by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was completely prevented by pretreatment of female A/J mice with 8-methoxypsoralen, a potent inhibitor of cytochrome P450 (P450 or CYP) 2A [Takeuchi et al. (2003) Cancer Res., 63, 7581-7583].
  • Thus, the aim of this study was to confirm that 8-methoxypsoralen exhibits chemopreventive effects by inhibiting CYP2A in the mouse lung.
  • The involvement of CYP2A in the metabolic activation of NNK in the lung was first evidenced by the fact that the mutagenic activation of NNK by mouse lung microsomes was inhibited by 8-methoxypsoralen, coumarin and antibodies to rat CYP2A1.
  • The expression of mRNA for CYP2A5, but not for CYP2A4 or CYP2A12, in the mouse lung was proven by reverse transcriptase-polymerase chain reaction, probably indicating that CYP2A5 present in the mouse lung was involved in the metabolic activation of NNK.
  • The in vivo chemopreventive effects of 8-methoxypsoralen towards NNK-induced adenoma was seen only when the agent was given to female A/J mice prior to, but not posterior to, NNK, lending support to the idea that NNK is activated by CYP2A5 in the mouse lung as an initial step to cause adenoma.
  • The inhibition by 8-methoxypsoralen of NNK-induced adenoma was seen in a dose-dependent manner: the dose to show apparent 50% suppression was calculated to be 1.0 mg/kg.
  • To our surprise, CYP2A protein(s) was expressed in the lesion of NNK-induced lung adenomas, probably suggesting that 8-methoxypsoralen could inhibit the possible occurrence of further mutation of the adenoma cells induced by NNK.
  • Based on these lines of evidence, we propose that 8-methoxypsoralen inhibits the CYP2A5-mediated metabolic activation of NNK in the mouse lung, leading to the prevention of NNK-induced adenoma.
  • [MeSH-major] Adenoma. Carcinogens / toxicity. Cytochrome P-450 Enzyme Inhibitors. Lung Neoplasms / chemically induced. Lung Neoplasms / prevention & control. Methoxsalen / therapeutic use. Nitrosamines / toxicity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 8-METHOXYPSORALEN .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • Hazardous Substances Data Bank. COUMARIN .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Carcinogenesis. 2005 Dec;26(12):2214
  • (PMID = 15958517.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinogens; 0 / Coumarins; 0 / Cytochrome P-450 Enzyme Inhibitors; 0 / Escherichia coli Proteins; 0 / Nitrosamines; 0 / Proteins; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 9035-51-2 / Cytochrome P-450 Enzyme System; A4VZ22K1WT / coumarin; EC 1.- / Mixed Function Oxygenases; EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.- / Cytochrome P-450 CYP2A6; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp2a4 protein, mouse; EC 1.14.14.1 / Cyp2a5 protein, mouse; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.22 / Gpt protein, E coli; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


3. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T: Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature; 2010 Nov 25;468(7323):572-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific sensitivity to p53 restoration during lung cancer progression.
  • Here we show that restoration of p53 in established murine lung tumours leads to significant but incomplete tumour cell loss specifically in malignant adenocarcinomas, but not in adenomas.
  • Our observations also underscore that the p53 pathway is not engaged by low levels of oncogene activity that are sufficient for early stages of lung tumour development.
  • [MeSH-major] Adenocarcinoma / physiopathology. Adenoma / physiopathology. Disease Progression. Lung Neoplasms / physiopathology. Tumor Suppressor Protein p53 / metabolism


Advertisement
4. Lee S, Choi H, Kim E, Kim H, Park YH, Yu DY, Yoon SJ, Kim J, Sheen Y, Park SN, Yoon DY: Melphalan inhibits adenoma development through modulating the expression of K-ras-specific markers in K-ras Tg mice. Int J Oncol; 2010 Jul;37(1):219-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melphalan inhibits adenoma development through modulating the expression of K-ras-specific markers in K-ras Tg mice.
  • It is well-known that mutated K-ras gene is involved in approximately 30% of human cancers such as lung cancer.
  • To search for K-ras oncogene-induced modulators in lung tissues of K-ras transgenic mice, we analyzed K-ras-specific genes and proteins related to cancer development, signal transduction, inflammation as well as tumor suppression in a previous study.
  • In this study, we investigated the modulating effects of genotoxic carcinogen treatment on expression of K-ras-dependent modulated genes and proteins in lung tissues of K-ras Tg mice.
  • In order to evaluate candidate K-ras markers modulated by genotoxic stress and to investigate whether a genotoxic carcinogen would enhance or inhibit carcinogenesis in lung tissues of the K-ras Tg mice, the anti-cancer drug melphalan was intraperitoneally injected into K-ras Tg mice every two days for four weeks.
  • These results suggest that melphalan inhibits carcinogenesis via modulating K-ras-specific genes and proteins expressed in the lung tissues of K-ras Tg mice.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic / drug effects. Genes, ras. Lung Neoplasms / pathology. Melphalan / pharmacology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514414.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; Q41OR9510P / Melphalan
  •  go-up   go-down


5. Waalkes MP, Liu J, Diwan BA: Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol; 2007 Aug 1;222(3):271-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In C3H mice, two separate studies show male offspring exposed to arsenic in utero developed liver carcinoma and adrenal cortical adenoma in a dose-related fashion during adulthood.
  • Prenatally exposed female C3H offspring show dose-related increases in ovarian tumors and lung carcinoma and in proliferative lesions (tumors plus preneoplastic hyperplasia) of the uterus and oviduct.
  • In addition, prenatal arsenic plus postnatal exposure to the tumor promoter, 12-O-tetradecanoyl phorbol-13-acetate (TPA) in C3H mice produces excess lung tumors in both sexes and liver tumors in females.
  • Overall this model has provided convincing evidence that arsenic is a transplacental carcinogen in mice with the ability to target tissues of potential human relevance, such as the urinary bladder, lung and liver.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Carcinog. 1997 Aug;19(4):236-42 [9290700.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):209-18 [9219559.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2293-8 [9450472.001]
  • [Cites] Toxicol Sci. 1998 Aug;44(2):185-90 [9742656.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1489-97 [9788961.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] Pediatr Nephrol. 1999 Feb;13(2):171-8 [10229008.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1873-6 [10469637.001]
  • [Cites] Exp Cell Res. 2005 Jan 1;302(1):96-107 [15541729.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17(12):1733-42 [15606151.001]
  • [Cites] Toxicol Sci. 2005 Feb;83(2):237-45 [15537745.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:269-477 [15645578.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):27-35 [15890234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2179-86 [16014701.001]
  • [Cites] Oncogene. 2005 Dec 15;24(56):8217-28 [16355251.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Jun 15;213(3):216-23 [16368122.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305 [16712894.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35 [10873715.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):135-45 [10963625.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):68-74 [11134545.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5389-95 [11454681.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71 [11578149.001]
  • [Cites] Environ Health Perspect. 2002 Apr;110(4):331-6 [11940449.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1387-97 [12151359.001]
  • [Cites] Chem Res Toxicol. 2002 Sep;15(9):1150-7 [12230408.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:767-71 [12426129.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):389-94 [12676588.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Dec 15;193(3):309-34 [14678742.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):599-603 [15064167.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):327-35 [15276412.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):142-50 [15313586.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Cancer Res. 1975 Mar;35(3):766-80 [1167809.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Nov 17;376(2):117-32 [145710.001]
  • [Cites] Carcinogenesis. 1981;2(11):1087-94 [6797749.001]
  • [Cites] Teratology. 1987 Feb;35(1):19-25 [3563933.001]
  • [Cites] Toxicol Pathol. 1988;16(3):340-9 [3194656.001]
  • [Cites] Cancer Lett. 1993 Feb;68(2-3):193-8 [8443792.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3874-6 [8358711.001]
  • [Cites] Pathology. 1994 Apr;26(2):154-60 [7522317.001]
  • [Cites] Carcinogenesis. 1995 Aug;16(8):1993-6 [7634431.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Carcinogenesis. 1997 Oct;18(10):2009-14 [9364013.001]
  • (PMID = 17306315.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z01 BC005488-21; United States / Intramural NIH HHS / / Z99 ES999999; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Arsenicals; 0 / Carcinogens; 0 / Estrogens; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS28781; NLM/ PMC1995036
  •  go-up   go-down


6. Lu G, Xiao H, You H, Lin Y, Jin H, Snagaski B, Yang CS: Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin Cancer Res; 2008 Aug 1;14(15):4981-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin.
  • PURPOSE: The present study investigated the possible synergistic inhibitory effect of a novel combination of polyphenon E (PPE, a standardized green tea polyphenol preparation) and atorvastatin (trade name Lipitor) in a mouse tumorigenesis model and in human lung cancer H1299 and H460 cell lines.
  • The interaction of these two agents was also studied in human lung cancer H1299 and H460 cells.
  • RESULTS: The individual agents, PPE or atorvastatin, were not effective in inhibiting lung tumorigenesis.
  • The inhibition was associated with enhanced apoptosis and suppressed myeloid cell leukemia 1 (Mcl-1) level in adenoma as determined by immunohistochemistry and Western blots.
  • CONCLUSIONS: The present work showed that PPE and atorvastatin synergistically inhibited 4-(methylnitrosaminao)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in mice and the growth of lung cancer H1299 and H460 cells, possibly through enhanced apoptosis.
  • The results provide leads for future research on the application of this combination for the prevention and treatment of lung cancer.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676773.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120915; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NCI NIH HHS / CA / CA88961; United States / NIEHS NIH HHS / ES / ES50522; United States / NCI NIH HHS / CA / CA72720
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Phenols; 0 / Plant Extracts; 0 / Polyphenols; 0 / Pyrroles; 0 / Tea; 0 / polyphenon E; 48A5M73Z4Q / Atorvastatin Calcium; 8R1V1STN48 / Catechin
  •  go-up   go-down


7. Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M: Hurthle cell tumours of the thyroid. Personal experience and review of the literature. Acta Otorhinolaryngol Ital; 2009 Dec;29(6):305-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis of the malignant type of the tumour is still under debate as some Authors have reported that Hurthle cell adenoma occasionally behaves like Hurthle cell carcinoma.
  • From 1992 to 2003, the Authors identified 28 patients affected by Hurthle cell tumour, 9 with Hurthle cell adenoma and 19 with Hurthle cell carcinoma.
  • Mean age of patients affected by adenoma was 49.7 years (range 30-72) vs. 49.3 years (range 15-72) in Hurthle cell carcinoma patients.
  • Relapse was not observed in any of the cases with adenoma.
  • Only one Hurthle cell carcinoma patient showed distant lung metastases at 60 months' follow-up.
  • None of the patients with Hurthle cell adenoma showed a relapse or death caused by the tumour.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Aug;24(8):898-906 [10865033.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2616-25 [11352953.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):243-9 [11408821.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):911-7 [11420462.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1160-3 [11571953.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):331-5 [12057113.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2178-80 [12461336.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Feb;129(2):207-10 [12578450.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Endocr J. 2004 Jun;51(3):265-77 [15256771.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):307-12 [15468114.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(3):165-8 [15493577.001]
  • [Cites] Surg Gynecol Obstet. 1974 Oct;139(4):555-60 [4479589.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):851-5 [6503367.001]
  • [Cites] Surg Gynecol Obstet. 1985 May;160(5):409-13 [3992444.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Oct;61(4):773-8 [2993348.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1613-7 [3948132.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):101-22 [3843689.001]
  • [Cites] Arch Surg. 1988 Jul;123(7):849-54 [3382350.001]
  • [Cites] World J Surg. 1988 Aug;12(4):488-95 [3048000.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] Mayo Clin Proc. 1991 Jan;66(1):11-22 [1988751.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1944-53 [1913544.001]
  • [Cites] Acta Pathol Jpn. 1992 May;42(5):305-15 [1636432.001]
  • [Cites] Surg Clin North Am. 1995 Jun;75(3):395-403 [7747248.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2946-53 [7559879.001]
  • [Cites] Surgery. 1995 Dec;118(6):1131-6; discussion 1136-8 [7491533.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):761-801 [8608779.001]
  • [Cites] Surgery. 1996 Dec;120(6):1000-4; discussion 1004-5 [8957486.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):542-6 [9563543.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):893-910 [9735140.001]
  • [Cites] Surgery. 1998 Dec;124(6):967-74 [9854570.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):329-37 [15536332.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2842-6 [18665423.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):230-4 [18722077.001]
  • [Cites] Otolaryngol Head Neck Surg. 2009 May;140(5):715-9 [19393417.001]
  • [Cites] Diagn Cytopathol. 2009 Aug;37(8):600-6 [19526577.001]
  • (PMID = 20463834.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] Thyroid cancer, Hurthle cell
  • [Other-IDs] NLM/ PMC2868205
  • [Keywords] NOTNLM ; Hurthle cell adenoma / Hurthle cell carcinoma / Thyroid
  •  go-up   go-down


8. Matsuo T, Yusuke Kimura N, Takamori S, Shirouzu K: Recurrent pulmonary mucinous cystadenoma. Eur J Cardiothorac Surg; 2005 Jul;28(1):176-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pulmonary mucinous cystadenoma.
  • A pulmonary mucinous cyst adenoma is rare and there has been no report of the recurrence.
  • We report a case of a 56-year-old female who had recurrent pulmonary mucinous cystadenoma.
  • She had previously received a partial resection of the lung for a pulmonary mucinous cystadenoma 20 years ago.
  • On this admission, a chest X-ray and CT scan revealed a large pulmonary mass, and a lung resection was performed.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939602.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Furuse J, Saito H, Tsuyuguchi T, Yamamoto M, Kayahara M, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Hirano S, Amano H, Miura F, Japanese Association of Biliary Surgery, Japanese Society of Hepato-Biliary-Pancreatic Surgery, Japan Society of Clinical Oncology: Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg; 2008;15(1):41-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the presence of metastasis to the liver, lung, peritoneum, or distant lymph nodes, curative resection is not suitable.
  • Pancreaticoduodenectomy is indicated for ampullary carcinoma, and limited operation is also indicated for carcinoma in adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2003 Nov;238(5):720-7 [14578735.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):248-51 [14760676.001]
  • [Cites] World J Surg. 2004 Feb;28(2):160-5 [14708053.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):672-4 [15143890.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):95-101 [15213624.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):232-8 [15368106.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):239-44 [15368107.001]
  • [Cites] Surg Gynecol Obstet. 1986 Feb;162(2):153-8 [3945893.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):72-3 [3947884.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Am J Gastroenterol. 1987 Nov;82(11):1169-71 [3673996.001]
  • [Cites] Surgery. 1990 May;107(5):521-7 [2333592.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] World J Surg. 1990 Jul-Aug;14(4):535-43; discussion 544 [2166381.001]
  • [Cites] Surgery. 1990 Sep;108(3):572-80 [2204130.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):31-8 [1309988.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):326-31 [1558412.001]
  • [Cites] Ann Surg. 1992 Apr;215(4):344-9 [1558415.001]
  • [Cites] World J Surg. 1993 Mar-Apr;17(2):250-5 [8511922.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1210-6 [15685618.001]
  • [Cites] Surgery. 2005 Apr;137(4):396-402 [15800484.001]
  • [Cites] Ann Surg. 2005 May;241(5):693-9; discussion 699-702 [15849505.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):739-43 [16082591.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):28-32 [16371733.001]
  • [Cites] J Am Coll Surg. 2006 Jan;202(1):87-92 [16377501.001]
  • [Cites] Br J Surg. 2006 Feb;93(2):221-5 [16363020.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):186-92 [16455449.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):364-72 [16495702.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):99-105 [16794394.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):240-7 [16858186.001]
  • [Cites] Am Surg. 2006 Jul;72(7):599-604; discussion 604-5 [16875081.001]
  • [Cites] Surgery. 2007 May;141(5):581-8 [17462457.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(4):345-50 [17653631.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(4):351-7 [17653632.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):1052-7 [18043110.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):2-6 [18274838.001]
  • [Cites] Ann Surg. 1999 Nov;230(5):663-71 [10561090.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):575-83 [10589594.001]
  • [Cites] Am J Surg. 1995 Jun;169(6):589-94 [7771622.001]
  • [Cites] Surgery. 1995 Jun;117(6):616-23 [7778025.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):758-63 [7571677.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):632-7 [7487210.001]
  • [Cites] J Am Coll Surg. 1995 Dec;181(6):504-10 [7582223.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5 [8554135.001]
  • [Cites] Ann Surg. 1996 Jan;223(1):77-83 [8554422.001]
  • [Cites] Ann Surg. 1996 Apr;223(4):384-94 [8633917.001]
  • [Cites] Surgery. 1996 May;119(5):498-504 [8619203.001]
  • [Cites] Br J Surg. 1996 Apr;83(4):478-81 [8665234.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):808-18; discussion 819 [10615936.001]
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):55-66 [10674450.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):418-22 [10759735.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):122-7 [10982603.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):135-41 [10982605.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):155-62 [10982608.001]
  • [Cites] Langenbecks Arch Surg. 2000 Dec;385(8):509-14 [11201006.001]
  • [Cites] J Am Coll Surg. 2001 Feb;192(2):189-95 [11220719.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):385-92 [11224627.001]
  • [Cites] J Am Coll Surg. 2001 May;192(5):600-7 [11333097.001]
  • [Cites] Br J Surg. 2001 May;88(5):675-8 [11350438.001]
  • [Cites] Langenbecks Arch Surg. 2001 Mar;386(2):110-7 [11374043.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Jun;11(3):176-81 [11444747.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):179-84 [11856130.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):4-10 [11869005.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):392-9 [11882761.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(6):511-7 [11956901.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(6):525-9 [11956903.001]
  • [Cites] Surgery. 1994 Apr;115(4):445-51 [8165536.001]
  • [Cites] Hepatology. 1995 Feb;21(2):434-9 [7843717.001]
  • [Cites] Surgery. 1995 Apr;117(4):429-34 [7716725.001]
  • [Cites] Eur J Surg Oncol. 1996 Aug;22(4):366-71 [8783654.001]
  • [Cites] Arch Surg. 1996 Sep;131(9):981-4; discussion 985 [8790169.001]
  • [Cites] Eur Surg Res. 1996;28(5):333-40 [8880122.001]
  • [Cites] Surgery. 1996 Nov;120(5):816-21 [8909516.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):628-38 [8916878.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):639-46 [8916879.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Apr;5(2):317-36 [9019354.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):26-34 [8988723.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):892-9 [9041150.001]
  • [Cites] Surgery. 1997 Jun;121(6):611-7 [9186460.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):1012-6 [9240155.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):661-7 [9264348.001]
  • [Cites] Surg Today. 1997;27(8):710-3 [9306584.001]
  • [Cites] Hepatology. 1997 Nov;26(5):1176-81 [9362359.001]
  • [Cites] Cancer. 1997 Nov 15;80(10):1904-9 [9366291.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):62-8 [9426519.001]
  • [Cites] Surgery. 1998 Feb;123(2):131-6 [9481397.001]
  • [Cites] Surgery. 1998 Nov;124(5):831-8 [9823395.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):76-83 [9923803.001]
  • [Cites] Eur J Surg. 1999 Mar;165(3):215-22 [10231654.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Semin Surg Oncol. 1999 Jun;16(4):327-31 [10332779.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1547-51 [10430292.001]
  • [Cites] World J Surg. 1999 Oct;23(10):989-95; discussion 996-7 [10512937.001]
  • [Cites] Surgery. 2004 Nov;136(5):1012-7; discussion 1018 [15523394.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):77-84 [15621994.001]
  • [Cites] Radiology. 2005 Feb;234(2):625-30 [15591428.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):215-25 [15713922.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):50-6; discussion 56-7 [11986018.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(2):256-60 [12140616.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1130-6 [12190678.001]
  • [Cites] J Vasc Interv Radiol. 2002 Dec;13(12):1233-7 [12471187.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(5):569-75 [12541042.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):208-17 [12560779.001]
  • [Cites] World J Surg. 2003 Mar;27(3):272-7 [12607050.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):447-54 [12734095.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):694-7 [12808616.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):73-83 [12832968.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):84-92 [12832969.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):741-50; discussion 750 [12860755.001]
  • [Cites] Surg Today. 2003;33(10):740-2 [14513320.001]
  • (PMID = 18274843.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2794356
  • [Investigator] Kai M; Kimura Y; Sawada S; Shimizu H; Nakagawara H; Nakachi K; Yoshitome H; Saisyo H; Ryu M; Shikata S; Nimura Y
  •  go-up   go-down


10. Campisi J: Suppressing cancer: the importance of being senescent. Science; 2005 Aug 5;309(5736):886-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma / genetics. Animals. Biomarkers. Biomarkers, Tumor. DNA Damage. Disease Models, Animal. Genes, p53. Genes, ras. Humans. Lung Neoplasms / genetics. Methyltransferases / genetics. Methyltransferases / physiology. Mice. Mutation. Proto-Oncogene Proteins B-raf / genetics. Repressor Proteins / genetics. Repressor Proteins / physiology. Telomere

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16081723.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 2.1.1. / SUV39H1 protein, human; EC 2.1.1. / Suv39h1 protein, mouse; EC 2.1.1.- / Methyltransferases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


11. Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, Dixon DA, Zhang J, Hebert JR: Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis; 2009 Jun;24(6):647-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma.
  • MATERIALS AND METHODS: In a community-, colonoscopy-based case-control study with 162 incident, sporadic colorectal adenoma cases and 211 controls, we investigated associations of two promoter polymorphisms (-842 A > G in COX1 and -765 G > C in COX2) and two polymorphisms in the 3'-UTR of COX2 (8473 T > C and 9850 A > G) with risk of adenomas.
  • Multiple logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) of colorectal adenoma after adjusting for potential confounders.
  • CONCLUSION: These results suggest that the C allele of COX2 8473 T > C polymorphism may interact with NSAIDs to reduce risk for colorectal adenoma.
  • [MeSH-major] Adenoma / enzymology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Cyclooxygenase 1 / genetics. Cyclooxygenase 2 / genetics. Genetic Predisposition to Disease. Polymorphism, Single Nucleotide / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3421S-3426S [15570048.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Carcinogenesis. 2005 Mar;26(3):579-85 [15564289.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9 [15767339.001]
  • [Cites] Lung Cancer. 2005 Apr;48(1):11-7 [15777967.001]
  • [Cites] Cancer Lett. 2005 Aug 8;226(1):49-54 [15882925.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):953-9 [16205694.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):668-72 [16506214.001]
  • [Cites] BMC Cancer. 2006;6:70 [16542464.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):297-303 [16482563.001]
  • [Cites] Breast Cancer Res. 2006;8(6):R71 [17181859.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):849-57 [17236225.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1197-201 [17151091.001]
  • [Cites] Cancer Sci. 2008 Mar;99(3):576-81 [18167131.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7908-16 [10630643.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):545-53 [10666384.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78 [10722929.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11750-7 [10766797.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):394-403 [11207158.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3971-6 [11751489.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1631-6 [12377741.001]
  • [Cites] Biomed Pharmacother. 2002 Oct;56(8):380-7 [12442910.001]
  • [Cites] Clin Pharmacol Ther. 2003 Jan;73(1):122-30 [12545150.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):985-90 [12771044.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):141-9 [14619964.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Curr Pharm Des. 2004;10(6):635-46 [14965326.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):665-73 [15054679.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1760-4 [15150618.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):339-43 [15173859.001]
  • [Cites] Am J Epidemiol. 1985 Jul;122(1):51-65 [4014201.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Jan 29;190(2):406-11 [8427584.001]
  • [Cites] Am J Epidemiol. 1993 Jun 1;137(11):1241-50 [8322764.001]
  • [Cites] Biochem J. 1994 Sep 15;302 ( Pt 3):723-7 [7945196.001]
  • [Cites] Int J Epidemiol. 1995 Apr;24(2):389-98 [7635601.001]
  • [Cites] Med Sci Sports Exerc. 1997 Jun;29(6 Suppl):S1-205 [9243481.001]
  • [Cites] Jpn J Clin Oncol. 1998 Jul;28(7):421-6 [9739782.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):449-57 [15550453.001]
  • (PMID = 19205707.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA134609; United States / NCRR NIH HHS / RR / RR017698; United States / NCI NIH HHS / CA / 1 U01 CA114601-01; United States / NCI NIH HHS / CA / R01CA-51932
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ NIHMS377403; NLM/ PMC3461962
  •  go-up   go-down


12. Ritchie KJ, Henderson CJ, Wang XJ, Vassieva O, Carrie D, Farmer PB, Gaskell M, Park K, Wolf CR: Glutathione transferase pi plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane. Cancer Res; 2007 Oct 01;67(19):9248-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione transferase pi plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane.
  • Such environmental factors are well defined for smoking-induced lung cancer; however, the roles of specific genes have still to be elucidated.
  • Activity-altering polymorphisms in Gstp have therefore been speculated to be potential risk modifiers in lung cancer development.
  • To clearly establish a role for GSTP in lung tumorigenesis, we investigated whether deletion of the murine Gstp genes (Gstp1 and Gstp2) alters susceptibility to chemically induced lung tumors following exposure to BaP, 3-methylcholanthrene (3-MC), and urethane.
  • In Gstp-null mice, the capacity of pulmonary cytosol to catalyze conjugation of the BaP diol epoxide was significantly reduced.
  • Concomitant with this, a significant increase in the level of BaP DNA adducts was measured in the lungs of null animals; however, no increase in DNA adducts was measured in the case of 3-MC exposure, suggesting that an alternative protective pathway exists.
  • Indeed, significant differences in pulmonary gene expression profiles were also noted between wild-type and null mice.
  • This is the first report to establish a clear correlation between Gstp status and lung cancer in vivo.
  • [MeSH-major] Adenoma / chemically induced. Adenoma / enzymology. Carcinogens. Glutathione S-Transferase pi / metabolism. Lung Neoplasms / chemically induced. Lung Neoplasms / enzymology
  • [MeSH-minor] 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide. Animals. Benzo(a)pyrene. DNA Adducts / biosynthesis. Female. Gene Expression Profiling. Lung / metabolism. MAP Kinase Kinase 4 / metabolism. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Tobacco. Urethane


13. Zitt M, Zitt M, Müller HM: DNA methylation in colorectal cancer--impact on screening and therapy monitoring modalities? Dis Markers; 2007;23(1-2):51-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations have been associated with specific steps in this adenoma-carcinoma sequence and are believed to drive the histological progression of CRC.
  • Furthermore, early detection of progression of disease in patients having had CRC permits immediate commencement of specific treatment regimens (e.g. curative resection of liver and lung metastases) and probably longer survival and better quality of life.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325426.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 160
  • [Other-IDs] NLM/ PMC3851076
  •  go-up   go-down


14. Pinsky PF, Schoen RE, Weissfeld JL, Church T, Yokochi LA, Doria-Rose VP, Prorok P: The yield of surveillance colonoscopy by adenoma history and time to examination. Clin Gastroenterol Hepatol; 2009 Jan;7(1):86-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The yield of surveillance colonoscopy by adenoma history and time to examination.
  • METHODS: A sample of subjects in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial with abnormal flexible sigmoidoscopy and follow-up colonoscopy were queried about subsequent surveillance colonoscopy over a 10-year period.
  • Subjects with advanced adenomas, nonadvanced adenoma, nonadenomatous polyps, and no polyps at baseline were included.
  • RESULTS: At the first surveillance, 10.5% had advanced adenoma and 37% had any adenoma in the advanced adenoma group (n = 1057), compared with rates of 6.8% and 32% (nonadvanced adenoma: n = 765), 4.9% and 22% (nonadenomatous polyps: n = 658), and 3.1% and 16% (no polyps: n = 127) (P < .0001, linear trend test).
  • Mean (SD) time intervals (years) from baseline colonoscopy to first surveillance were 3.4 (2.0) for advanced adenoma, 4.3 (2.0) for nonadvanced adenoma, 4.5 (2.0) for nonadenomatous polyps, and 4.7 (2.0) for no polyps.
  • There were no increasing (or decreasing) trends in the observed rate of advanced adenoma or any adenoma with time to the initial surveillance examination in any baseline group.
  • Among subjects with a second surveillance examination, adenoma findings at both baseline and first surveillance influenced the rates of advanced adenoma and any adenoma at second surveillance.
  • The lack of association between recurrence rates and time to surveillance suggests limitations in our understanding of the biology of adenoma development.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonoscopy. Mass Screening / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829395.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


15. Zhang FW, Cheng HC, Jiang CD, Deng CY, Xiong YZ, Li FE, Lei MG: Imprinted status of pleomorphic adenoma gene-like I and paternal expression gene 10 genes in pigs. J Anim Sci; 2007 Apr;85(4):886-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imprinted status of pleomorphic adenoma gene-like I and paternal expression gene 10 genes in pigs.
  • In this study, the polymorphism-based approach was used to detect the expression patterns of the porcine pleomorphic adenoma gene-like I (PLAGL1) and paternal expression gene 10 (PEG10) genes.
  • Imprinting analysis indicated that the PLAGL1 and PEG10 genes were both paternally expressed in all tissues tested (heart, liver, spleen, lung, kidney, stomach, small intestine, skeletal muscle, fat, uterus, and ovary).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178803.001).
  • [ISSN] 1525-3163
  • [Journal-full-title] Journal of animal science
  • [ISO-abbreviation] J. Anim. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


16. Kim DH, Nagano Y, Choi IS, White JA, Yao JC, Rashid A: Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer; 2008 Jan;47(1):84-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used genome-wide high-density single nucleotide polymorphism (SNP) array analysis to detect copy number alterations in 29 WDNTs, including seven lung, seven nonileal gastrointestinal, and 15 ileal tumors, and compared with allelic imbalances in 15 pancreatic endocrine tumors (PETs).
  • Chromosomal aberrations were less common in WDNTs from lung and gastrointestinal tract compared to PETs (P = 0.001).
  • [MeSH-major] Adenoma, Islet Cell / genetics. Allelic Imbalance. Carcinoid Tumor / genetics. Cell Differentiation / genetics. Genome, Human. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Chromosome Aberrations. Female. Gastrointestinal Neoplasms / genetics. Humans. Ileal Neoplasms / genetics. Loss of Heterozygosity / genetics. Lung Neoplasms / genetics. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943967.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol; 2005 Dec;18(12):1591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GPC3 immunoreactivity was detected in only one of 23 metastatic lesions of colorectal carcinoma, and its expression was entirely absent in the liver cell adenoma (0/7), carcinoid tumor (0/1), and cholangiocellular carcinoma (0/16).
  • [MeSH-minor] Antibodies, Monoclonal / biosynthesis. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Glypicans. Hepatoblastoma / metabolism. Hepatoblastoma / pathology. Hepatocytes / metabolism. Hepatocytes / pathology. Humans. Liver / embryology. Liver / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920546.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Heparan Sulfate Proteoglycans
  •  go-up   go-down


18. Kamisawa T, Tu Y, Egawa N, Nakajima H, Tsuruta K, Okamoto A: Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol; 2005 Sep 28;11(36):5688-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnosis was confirmed in 30 cases (adenoma (n = 19) and adenocarcinoma (n = 11).
  • Major associated malignancies were gastric cancer (n = 12), colonic cancer (n = 7), esophageal cancer (n = 4), pulmonary cancer (n = 4), and independent pancreatic cancer (n = 3).
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Carcinoma, Pancreatic Ductal / complications. Colonic Neoplasms / complications. Esophageal Neoplasms / complications. Lung Neoplasms / complications. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237766.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4481489
  •  go-up   go-down


19. Floyd HS, Jennings-Gee JE, Kock ND, Miller MS: Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol Carcinog; 2006 Jul;45(7):506-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
  • Mutations in Ki-ras occur in approximately 30-50% of patients with adenocarcinoma (AC) of the lung.
  • We previously reported the development of a bitransgenic mouse model that expressed the human Ki-ras(G12C) allele in a lung-specific, tetracycline-inducible manner and gave rise to benign lung tumors.
  • In the current study, these benign tumors, which represent relatively early lesions in neoplastic progression, were analyzed for molecular alterations secondary to mutant Ki-ras expression to determine the gene(s) that contribute to adenoma (AD) development.
  • A subset of the lung tumors (8/28) displayed reduced levels of p16(Ink4a) expression (P = 0.02).
  • Immunohistochemical analysis confirmed the upregulation of p19(Arf) and survivin in all 10 of the lung tumors examined.
  • In addition, increased levels of activated p53 were found in lung tumor tissues stained with an anti-phospho-p53 antibody, while an absence of staining was observed with an anti-phospho-pRb antibody in both normal control and tumor tissue.
  • These data thus identify alterations in specific genes and pathways that combine with the mutation in Ki-ras to promote the formation of benign lung tumors and suggest potential targets for the development of novel chemotherapeutic and chemopreventive agents during the early stages of lung tumor progression.
  • [MeSH-major] Genes, ras / genetics. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide. ras Proteins / genetics


20. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H, Yasui W: Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol; 2005 Oct;207(2):185-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, lung cancers (n = 30) and breast cancers (n = 30) did not express Reg IV.
  • [MeSH-minor] Adenoma / chemistry. Biomarkers, Tumor / analysis. Blotting, Western / methods. Breast Neoplasms / chemistry. Carcinoid Tumor / chemistry. Cell Differentiation / physiology. Cell Line, Tumor. Colon / metabolism. Colorectal Neoplasms / chemistry. Female. Humans. Immunohistochemistry / methods. Intestine, Small / metabolism. Lung Neoplasms / chemistry. Pancreas / metabolism. Pancreatic Neoplasms / chemistry. Phenotype. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16086444.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Neoplasm Proteins; 0 / REG4 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


21. Zaffaroni D, Spinola M, Galvan A, Falvella FS, Pazzaglia S, Saran A, Mancuso MT, Galbiati F, Pignatiello C, Cabrera W, Ibanez O, Manenti G, Dragani TA: Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene; 2005 Feb 3;24(6):1084-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis.
  • Analysis of seven candidate genes mapping in the 1-Mb region of the mouse pulmonary adenoma resistance 4 (Par4) locus revealed a single amino-acid change, consisting in a nonconservative Arg968Cys variation in the juxtamembrane domain of the Met proto-oncogene-encoded protein.
  • Analysis of genomic DNA of 126 lung adenocarcinoma patients for the Met juxtamembrane domain revealed the same Arg/Cys variation at the mouse homologous position in one patient; two other patients carried additional variants in the same domain, suggesting a potential role for rare MET juxtamembrane variants in human lung cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / physiopathology. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / physiopathology. Cell Transformation, Neoplastic. Genetic Predisposition to Disease. Lung Neoplasms / genetics. Lung Neoplasms / physiopathology. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics


22. Duprez R, Thimon S, Kerdraon R, Bonneau C, Metois D, Michenet P: [Tumor-to-tumor metastasis: report of three cases]. Ann Pathol; 2009 Dec;29(6):507-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Métastases d'une tumeur dans une autre tumeur : à propos de trois cas.
  • We report three cases of tumor metastasizing in another tumor: a clear cell renal cell carcinoma in a vesicular thyroid adenoma, a lung carcinoma in a meningioma and a neuroendocrine lung carcinoma in a clear cell renal cell carcinoma.
  • According to the literature, clear cell renal cell carcinoma is the most common tumor recipient of metastasis while lung carcinoma is the most common donor tumor.
  • [MeSH-major] Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Metastasis / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20005442.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


23. Devesa SS, Bray F, Vizcaino AP, Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer; 2005 Nov 1;117(2):294-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.
  • Lung cancer rates have peaked among men in many areas of the world, but rates among women continue to rise.
  • Most lung cancers are squamous cell carcinoma, small cell carcinoma, or adenocarcinoma; trends vary according to type.
  • Rates of all lung cancer types among women and adenocarcinoma among men continue to rise despite declining cigarette use in many Western countries and shifts to filtered/low-tar cigarettes.
  • Renewed efforts toward cessation and prevention are mandatory to curb the prevalence of cigarette smoking and to reduce lung cancer rates eventually.
  • [MeSH-major] Adenoma / epidemiology. Lung Neoplasms / classification. Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900604.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. National Toxicology Program: Toxicology and carcinogenesis studies of divinylbenzene-HP (Cas No. 1321-74-0) in F344/N rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser; 2006 Nov;(534):1-290
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following combined analysis of single and step-section data, the incidences of renal tubule adenoma and adenoma or carcinoma (combined) were marginally higher in 200 and 400 ppm males, and the incidence of renal tubule hyperplasia was significantly increased in 400 ppm males.
  • The incidence of focal chronic inflammation in the lung of 400 ppm males was significantly greater than in the chamber control group.
  • The incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined) in 100 ppm males were greater than chamber control incidences, but the incidences of adenoma or carcinoma (combined) were within the historical control range.
  • The incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined) in all exposed groups of females were generally greater than those of the chamber controls; the incidences were at the upper end or exceeded the historical control ranges.
  • There was equivocal evidence of carcinogenic activity of divinylbenzene-HP in female B6C3F1 mice based on the incidences of alveolar/bronchiolar adenoma or carcinoma (combined) in the lung.
  • Exposure to divinylbenzene-HP caused nonneoplastic lesions of the nasal cavity in male and female rats and of the lung and nasal cavity in male and female mice.

  • Hazardous Substances Data Bank. VINYLSTYRENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342197.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vinyl Compounds; IZ715T4SBU / divinyl benzene
  •  go-up   go-down


25. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J: Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer; 2007 Jan;55(1):1-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.
  • PURPOSE: To review the evidence implicating the deregulation of cyclin D1 in the pathogenesis of non-small cell lung cancer (NSCLC), and to discuss the opportunities for targeted clinical intervention.
  • Genotype has been correlated with the risk and/or severity of disease or drug response across a range of malignancies, including lung cancer.
  • CONCLUSION: Current data indicate that cyclin D1 overexpression is not a consequence of, but rather a pivotal element in the process of malignant transformation in the lung and other tissues.
  • This understanding may open new avenues for lung cancer diagnosis, treatment and prevention.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / physiopathology. Cyclin D1 / genetics. Lung Neoplasms / pathology. Lung Neoplasms / physiopathology
  • [MeSH-minor] Adenoma / pathology. Adenoma / physiopathology. Cell Transformation, Neoplastic. Gene Expression Regulation, Neoplastic. Glioblastoma / pathology. Glioblastoma / physiopathology. Humans. Polymorphism, Genetic


26. Okamura M, Unami A, Matsumoto M, Oishi Y, Kashida Y, Mitsumori K: Gene expression analysis of urethane-induced lung tumors in ras H2 mice. Toxicology; 2006 Jan 16;217(2-3):129-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of urethane-induced lung tumors in ras H2 mice.
  • Subsequently, microarray and RT-PCR analyses for the transgene and some molecules involved in the Ras pathway were performed on the induced lung tumors.
  • In the microarray analysis, gene expression profiles of normal lungs and adenomas showed a distinct pattern, and several genes related to the cell cycle and nucleotide metabolism were up-regulated in the adenomas.
  • RT-PCR confirmed the overexpression of the transgene in lung tumors; however, the up-regulation of the mouse endogenous ras genes was not observed.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Genes, ras / genetics. Lung Neoplasms / genetics. Urethane / toxicity
  • [MeSH-minor] Adenoma / chemically induced. Adenoma / genetics. Adenoma / pathology. Animals. Cluster Analysis. Gene Expression Profiling / methods. Humans. Injections, Intraperitoneal. Male. Mice. Mice, Transgenic. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289808.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 3IN71E75Z5 / Urethane
  •  go-up   go-down


27. Dixon D, Herbert RA, Kissling GE, Brix AE, Miller RA, Maronpot RR: Summary of chemically induced pulmonary lesions in the National Toxicology Program (NTP) toxicology and carcinogenesis studies. Toxicol Pathol; 2008 Apr;36(3):428-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Summary of chemically induced pulmonary lesions in the National Toxicology Program (NTP) toxicology and carcinogenesis studies.
  • The lung is the second most common target site of neoplasia of chemicals tested by the National Toxicology Program (NTP).
  • Of all peer-reviewed NTP studies to date (N = 545), a total of sixty-four chemicals in sixty-six reports produced significant site-specific neoplasia in the lungs of rats and/or mice.
  • Of the studies associated with lung tumor induction, approximately 35% were inhalation and 35% were gavage studies, with dosed-feed, dosed-water, topical, intraperitoneal, or in utero routes of chemical administration accounting for 18%, 6%, 3%, 1%, and 1% of the studies, respectively.
  • The most commonly induced lung tumors were alveolar/bronchiolar (A/B) adenoma and/or carcinoma for both species.
  • The liver was the most common primary site of origin of metastatic lesions to the lungs of mice; however, skin was most often the primary site of origin of metastatic lesions to the lungs of rats.
  • In summary, A/B adenoma and carcinoma were the most frequently diagnosed chemically induced tumors in the lungs of both rats and mice in the NTP toxicology and carcinogenesis bioassays, and hyperplasia and inflammation were the most common nonneoplastic changes observed.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Carcinogens / toxicity. Lung Neoplasms / pathology. Neoplasms, Experimental / pathology. Xenobiotics / toxicity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Exp Toxicol Pathol. 2006 Aug;58(1):13-20 [16806863.001]
  • [Cites] Lab Invest. 1980 Jul;43(1):28-36 [7392573.001]
  • [Cites] Am J Pathol. 1981 May;103(2):174-80 [7234960.001]
  • [Cites] Cancer Lett. 1983 Apr;18(3):311-6 [6850563.001]
  • [Cites] Am J Pathol. 1985 Mar;118(3):493-9 [3883798.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2785-92 [3886137.001]
  • [Cites] Am J Pathol. 1989 Jan;134(1):79-87 [2464284.001]
  • [Cites] Exp Lung Res. 1991 Mar-Apr;17(2):263-78 [2050030.001]
  • [Cites] Toxicol Pathol. 1991;19(4 Pt 1):540-56 [1813992.001]
  • [Cites] Vet Pathol. 1994 May;31(3):366-74 [8053132.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:143-8 [8741774.001]
  • [Cites] Toxicol Pathol. 1996 Sep-Oct;24(5):564-72 [8923677.001]
  • [Cites] Prev Med. 1997 Jul-Aug;26(4):451-6 [9245665.001]
  • [Cites] Exp Toxicol Pathol. 1997 Dec;49(6):433-46 [9495643.001]
  • [Cites] Toxicol Pathol. 1998 Mar-Apr;26(2):298-300 [9547872.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):576-81 [15767332.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2006 Jan;(520):4-246 [16628245.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2006 Apr;(521):4-232 [16835633.001]
  • [Cites] Lab Invest. 1979 Jun;40(6):708-16 [449277.001]
  • (PMID = 18441259.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Xenobiotics
  • [Other-IDs] NLM/ NIHMS103829; NLM/ PMC2675557
  •  go-up   go-down


28. Hughes S, Williams RD, Webb E, Houlston RS: Meta-analysis and pooled re-analysis of copy number changes in colorectal cancer detected by comparative genomic hybridization. Anticancer Res; 2006 Sep-Oct;26(5A):3439-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. DNA, Neoplasm / genetics. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Neoplasm Staging. Nucleic Acid Hybridization. Peritoneal Neoplasms / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094464.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Comparative Study; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


29. Kuwahara M, Nagafuchi M, Rikimaru T, Iwasaki A, Shirakusa T: Pulmonary papillary adenoma. Gen Thorac Cardiovasc Surg; 2010 Oct;58(10):542-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary papillary adenoma.
  • We present a rare case of solitary pulmonary papillary adenoma.
  • The histological features were consistent with pulmonary papillary adenoma.
  • Only 20 cases of pulmonary papillary adenoma have been reported in the literature.
  • [MeSH-major] Adenoma / pathology. Lung Neoplasms / pathology. Solitary Pulmonary Nodule / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2000 Mar;436(3):289-95 [10782889.001]
  • [Cites] Arch Pathol Lab Med. 1991 Aug;115(8):797-801 [1863190.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(4):319-22 [8236829.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):134-9 [3006525.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1486-97 [7357529.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):243-8 [15085761.001]
  • [Cites] Pediatr Pulmonol. 1994 Jun;17(6):396-400 [8090612.001]
  • [Cites] Med Pediatr Oncol. 2002 Feb;38(2):125-7 [11813181.001]
  • [Cites] Am J Clin Pathol. 1992 Mar;97(3):393-7 [1543163.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2839-44 [7139574.001]
  • [Cites] Virchows Arch. 1996 Jun;428(3):195-200 [8688974.001]
  • [Cites] Respiration. 1993;60(6):373-7 [8290804.001]
  • (PMID = 20941571.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Skin Neoplasms / secondary


31. Wang MH, Lee W, Luo YL, Weis MT, Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol; 2007 Dec;213(4):402-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RON was almost exclusively expressed at variable levels in normal epithelial cells from the digestive track, lung, kidney, pancreas, liver, breast, bladder, skin, and others.
  • Among 15 types of cancer studied, RON was overexpressed in significant numbers in cancers derived from breast (56%), colon (51%), lung (48), thyroid (42%), skin (37%), bladder (36%), and pancreas (33%).
  • Detailed analysis of thyroid tissues showed that RON was hardly detected in normal thyroid cells, moderately expressed in adenoma samples, but overexpressed in about half of papillary and follicular cancer specimens.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Pathological Society of Great Britain and Ireland
  • (PMID = 17955509.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA91980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Neoplasm Proteins; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


32. Di Pace RF, Massa S, Ribeiro OG, Cabrera WH, De Franco M, Starobinas N, Seman M, Ibañez OC: Inverse genetic predisposition to colon versus lung carcinogenesis in mouse lines selected based on acute inflammatory responsiveness. Carcinogenesis; 2006 Aug;27(8):1517-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse genetic predisposition to colon versus lung carcinogenesis in mouse lines selected based on acute inflammatory responsiveness.
  • Mouse lines produced by bidirectional selection on the basis of maximum (AIRmax) or minimum (AIRmin) acute inflammatory reactions were examined for the development of chemically induced acute colitis and colon tumors and the development of lung tumors.
  • At the latter time point, however, multiple lung adenomas and large adenocarcinomas were found in AIRmin but not in AIRmax mice.
  • The results demonstrate that genetic determinants of the inflammatory response differentially influence susceptibility to colon and lung carcinogenesis in the AIRmax and AIRmin mouse model.
  • [MeSH-major] Cell Transformation, Neoplastic. Colitis / genetics. Colonic Neoplasms / genetics. Genetic Predisposition to Disease / genetics. Immunity, Cellular / genetics. Inflammation / genetics. Lung Neoplasms / genetics
  • [MeSH-minor] 1,2-Dimethylhydrazine / toxicity. Acute Disease. Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenocarcinoma / immunology. Adenoma / chemically induced. Adenoma / genetics. Adenoma / immunology. Animals. Antiviral Agents / toxicity. Carcinogens / toxicity. Cells, Cultured. Crosses, Genetic. Cytokines / metabolism. Dextran Sulfate / toxicity. Disease Models, Animal. Mice. Mice, Inbred Strains

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16774945.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Carcinogens; 0 / Cytokines; 9042-14-2 / Dextran Sulfate; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


33. Dong YC, Wu B, Wang JD, Rao Q, Ma HH, Zhang RS, Zhou HB, Lu ZF, Zhou XJ: [Expression and clinical significance of kidney injury molecule-1 in renal epithelial neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / metabolism. Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Chromosomes, Human, X. Gene Fusion. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Retrospective Studies. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388397.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / CDH16 protein, human; 0 / Cadherins; 0 / HAVCR1 protein, human; 0 / Membrane Glycoproteins; 0 / Receptors, Virus; 0 / TFE3 protein, human
  •  go-up   go-down


34. Shikishima K, Kawai K, Kitahara K: Pathological evaluation of orbital tumours in Japan: analysis of a large case series and 1379 cases reported in the Japanese literature. Clin Exp Ophthalmol; 2006 Apr;34(3):239-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common primary tumour was malignant lymphoma (12%) followed by pleomorphic adenoma (7%).
  • Carcinomas from the lung, breast and thyroid were found to predominate among orbital metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671904.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Ricchetti T, Paci M, Cavazza A, Ferrari G, Annessi V, De Franco S, Sgarbi G: A case of metastatic epithelioid angiosarcoma in the lamina propria of a sigmoid tubulovillous adenoma. Tumori; 2005 Mar-Apr;91(2):210-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic epithelioid angiosarcoma in the lamina propria of a sigmoid tubulovillous adenoma.
  • It is generally a secondary tumor and the preferred sites of such metastases are the heart, pericardium, lung, breast, liver, spleen, bone, and brain.
  • In rare cases the lung has been described as the primary site.
  • We report a case of epithelioid angiosarcoma with multiple bilateral lung infiltration, bone metastasis, and metastasis of the lamina propria of a tubulovillous adenoma of the colon.
  • [MeSH-major] Adenoma / pathology. Basement Membrane / pathology. Epithelioid Cells / pathology. Hemangiosarcoma / pathology. Hemangiosarcoma / secretion. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948556.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Endothelial Cell Adhesion Molecule-1
  •  go-up   go-down


36. D'Agostini F, Mastracci L, Izzotti A, Balansky R, Pennisi TM, Steele VE, De Flora S: Modulation by phenethyl isothiocyanate and budesonide of molecular and histopathologic alterations induced by environmental cigarette smoke in mice. Cancer Prev Res (Phila); 2009 Jun;2(6):546-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our discovery that the perinatal period involves nucleotide modifications and gene overexpression in mouse lung prompted us to evaluate whether mice may become more susceptible to cigarette smoke when exposure starts immediately after birth.
  • However, after 4 months of exposure to ECS followed by 7 months of recovery in filtered air, the lung tumor yield was rather low.
  • After weanling, the mice exposed to ECS since birth underwent a variety of alterations of molecular and cytogenetical end points, and 11 months after birth, they exhibited significant histopathologic changes, such as pulmonary anthracosis, emphysema, hemorrhagic areas, alveolar bronchiolarization, bronchial hyperplasia, and tumors, both benign and malignant.
  • Both phenethyl isothiocyanate and budesonide, administered daily with the diet after weanling, attenuated several alterations of ECS-related biomarkers and moderately protected the lungs from histopathologic alterations, including tumors.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Budesonide / therapeutic use. Isothiocyanates / therapeutic use. Lung Neoplasms / prevention & control. Tobacco Smoke Pollution / adverse effects
  • [MeSH-minor] Adenoma / etiology. Adenoma / prevention & control. Age Factors. Animals. Animals, Newborn. Apoptosis / drug effects. Bone Marrow Cells / drug effects. Bone Marrow Cells / pathology. Carcinoma / etiology. Carcinoma / prevention & control. DNA Adducts / analysis. Drug Screening Assays, Antitumor. Epithelial Cells / drug effects. Epithelial Cells / pathology. Female. Lung / chemistry. Lung / drug effects. Lung Diseases / drug therapy. Lung Diseases / pathology. Male. Mice. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology. Pregnancy. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491290.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN53301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / DNA Adducts; 0 / Isothiocyanates; 0 / Tobacco Smoke Pollution; 51333-22-3 / Budesonide; 6U7TFK75KV / phenethyl isothiocyanate
  •  go-up   go-down


37. National Toxicology Program: Toxicology and carcinogenesis studies of methylene blue trihydrate (Cas No. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser; 2008 May;(540):1-224
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymus and lung weights of 50, 100, and 200 mg/kg males (except relative lung weight at 100 mg/kg) were significantly less than those of the vehicle controls.
  • The incidences of pancreatic islet cell adenoma and adenoma or carcinoma (combined) were increased in all dosed groups of males, were significantly increased in 25 mg/kg males, and exceeded the historical range in controls (all routes).
  • The incidences of carcinoma and of adenoma or carcinoma (combined) of the small intestine occurred with a positive trend in males.

  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685714.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Mutagens; T42P99266K / Methylene Blue
  •  go-up   go-down


38. Svajdler M, Bohus P, Goc V, Tkácová V: [Perivascular epithelioid cell tumor (PEComa) of the liver: a case report and review of the literature]. Cesk Patol; 2007 Jan;43(1):18-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By immunohistochemistry and genetics it belongs to the family of tumours which comprises angiomyolipoma, clear cell "sugar" tumor of lung, lymphangioleiomyomatosis and clear cell myomelanotic tumor of ligamentum falciforme/teres hepatis.
  • The main differential diagnosis of hepatic PEComa includes clear cell variant of liver cell adenoma and hepatocellular carcinoma, metastases of various clear cell carcinomas and metastasis of malignant melanoma.


39. Wang IC, Meliton L, Tretiakova M, Costa RH, Kalinichenko VV, Kalin TV: Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene; 2008 Jul 10;27(30):4137-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
  • The forkhead box m1 (Foxm1 or Foxm1b) protein (previously called HFH-11B, Trident, Win or MPP2) is abundantly expressed in human non-small cell lung cancers where it transcriptionally induces expression of genes essential for proliferation of tumor cells.
  • Lung tumors were induced in Rosa26-Foxm1 mice using the 3-methylcholanthrene (MCA)/butylated hydroxytoluene (BHT) lung tumor initiation/promotion protocol.
  • Elevated tumor formation in Rosa26-Foxm1 transgenic lungs was associated with persistent pulmonary inflammation, macrophage infiltration and increased expression of cyclooxygenase-2 (Cox-2), Cdc25C phosphatase, cyclin E2, chemokine ligands CXCL5, CXCL1 and CCL3, cathepsins and matrix metalloprotease-12.
  • Cell culture experiments with A549 human lung adenocarcinoma cells demonstrated that depletion of Foxm1 by either short interfering RNA transfection or treatment with Foxm1-inhibiting ARF 26-44 peptide significantly reduced Cox-2 expression.
  • [MeSH-major] Adenoma / genetics. Forkhead Transcription Factors / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2,6-DI-T-BUTYL-P-CRESOL .
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18345025.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 54687-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Foxm1 protein, mouse; 1P9D0Z171K / Butylated Hydroxytoluene; 56-49-5 / Methylcholanthrene; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


40. National Toxicology Program: NTP Toxicology and carcinogenesis studies of bromodichloromethane (CAS No. 75-27-4) in male F344/N rats and female B6C3F1 mice (Drinking Water Studies). Natl Toxicol Program Tech Rep Ser; 2006 Feb;(532):1-248
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Absolute lung weights of mice in the 350 and 750 mg/L groups were significantly less than that of the controls.
  • The incidences of hepatocellular adenoma or carcinoma (combined) occurred with a negative trend, and the incidence in the 700 mg/L group was significantly decreased relative to the control group.

  • Hazardous Substances Data Bank. BROMODICHLOROMETHANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741555.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Mutagens; 0 / Trihalomethanes; 7LN464CH2O / bromodichloromethane
  •  go-up   go-down


41. Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ: Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol; 2009 Apr;40(4):443-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.
  • Lung cancer is the leading cause of cancer deaths in the United States.
  • In addition to genetic abnormalities induced by cigarette smoke, several epidemiologic studies have found that smokers with chronic obstructive pulmonary disease (COPD), an inflammatory disease of the lungs, have an increased risk of lung cancer (1.3- to 4.9-fold) compared to smokers without COPD.
  • This suggests a link between chronic airway inflammation and lung carcinogenesis, independent of tobacco smoke exposure.
  • We studied this association by assaying the inflammatory impact of products of nontypeable Haemophilus influenzae, which colonizes the airways of patients with COPD, on lung cancer promotion in mice with an activated K-ras mutation in their airway epithelium.
  • Two new mouse models of lung cancer were generated by crossing mice harboring the LSL-K-ras(G12D) allele with mice containing Cre recombinase inserted into the Clara cell secretory protein (CCSP) locus, with or without the neomycin cassette excised (CCSP(Cre) and CCSP(Cre-Neo), respectively).
  • Lung lesions in CCSP(Cre-Neo)/LSL-K-ras(G12D) and CCSP(Cre)/LSL-K-ras(G12D) mice appeared at 4 and 1 month of age, respectively, and were classified as epithelial hyperplasia of the bronchioles, adenoma, and adenocarcinoma.
  • Weekly exposure of CCSP(Cre)/LSL-K-ras(G12D) mice to aerosolized nontypeable Haemophilus influenzae lysate from age 6-14 weeks resulted in neutrophil/macrophage/CD8 T-cell-associated COPD-like airway inflammation, a 3.2-fold increase in lung surface tumor number (156 +/- 9 versus 45 +/- 7), and an increase in total lung tumor burden.
  • We conclude that COPD-like airway inflammation promotes lung carcinogenesis in a background of a G12D-activated K-ras allele in airway secretory cells.

  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5054-8 [15289303.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Dec 1;164(11):2114-9 [11739144.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):949-57 [11698399.001]
  • [Cites] Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2 [11866137.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Eur Respir J. 2002 Sep;20(3):556-63 [12358328.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45547-57 [12237307.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Feb 15;167(4):587-92 [12433671.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Oct;31(4):382-94 [15191915.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):297-305 [15380520.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Med Clin North Am. 2004 Nov;88(6):1535-52, xi [15464112.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):433-9 [15489136.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):503-7 [3752756.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):512-8 [3826952.001]
  • [Cites] Am J Physiol. 1991 Aug;261(2 Pt 1):L70-6 [1872417.001]
  • [Cites] J Natl Cancer Inst Monogr. 1992;(13):23-9 [1327034.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):432-8 [8319174.001]
  • [Cites] J Leukoc Biol. 1995 Mar;57(3):375-8 [7884307.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1316-20 [7551388.001]
  • [Cites] J Histochem Cytochem. 1996 Aug;44(8):919-27 [8756763.001]
  • [Cites] Toxicol Lett. 1996 Nov;88(1-3):109-13 [8920724.001]
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):145-55 [9040936.001]
  • [Cites] Chest. 1997 Apr;111(4):885-90 [9106565.001]
  • [Cites] Eur Respir J. 1999 Nov;14(5):1015-22 [10596683.001]
  • [Cites] Semin Respir Infect. 2000 Mar;15(1):41-51 [10749549.001]
  • [Cites] Genesis. 2000 Nov-Dec;28(3-4):106-10 [11105051.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Am J Respir Crit Care Med. 2001 May;163(6):1304-9 [11371392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8774-9 [11438700.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 1997 Aug;97(2):229-32 [9344234.001]
  • [Cites] Chest. 1998 Apr;113(4 Suppl):235S-241S [9552012.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):885-90 [9615736.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1739-50 [9802985.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17723-8 [16317067.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2105-12 [16288213.001]
  • [Cites] Mol Cancer Res. 2006 Apr;4(4):221-33 [16603636.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 1;173(9):1016-22 [16456147.001]
  • [Cites] Eur Respir J. 2006 Sep;28(3):523-32 [16611654.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):734-42 [17322026.001]
  • [Cites] Swiss Med Wkly. 2007 Jun 2;137(21-22):304-11 [17629808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1119-27 [18281487.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jun;38(6):629-38 [18096867.001]
  • [Cites] PLoS One. 2008;3(5):e2220 [18493606.001]
  • [Cites] Genesis. 2008 Jun;46(6):300-7 [18543320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1193-9 [11700268.001]
  • (PMID = 18927348.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01 CA105352
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Bacterial Proteins; 0 / Chemokines; 0 / NF-kappa B; 0 / Porins; 0 / Scgb1a1 protein, mouse; 0 / ompP2 protein, Haemophilus influenzae; 9060-09-7 / Uteroglobin; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2660561
  •  go-up   go-down


42. Lees NP, Harrison KL, Hall CN, Margison GP, Povey AC: Human colorectal mucosal O6-alkylguanine DNA-alkyltransferase activity and DNA-N7-methylguanine levels in colorectal adenoma cases and matched referents. Gut; 2007 Mar;56(3):380-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colorectal mucosal O6-alkylguanine DNA-alkyltransferase activity and DNA-N7-methylguanine levels in colorectal adenoma cases and matched referents.
  • Such mutations are frequently seen in the KRAS oncogene of large colorectal adenomas, but whether adenoma or mutational risk in humans is influenced by MGMT activity and alkylating agent exposure is unclear.
  • Elevated MGMT levels were associated with an increased risk of adenoma (OR 1.17, 95% CI 1.03 to 1.33 per unit increase in activity).
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Guanine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1993 Jan;14(1):151-4 [8425264.001]
  • [Cites] Mutat Res. 1994 Mar;314(2):99-113 [7510369.001]
  • [Cites] J Biol Chem. 1994 Jun 24;269(25):17228-37 [8006031.001]
  • [Cites] Biochemistry. 1996 Jan 30;35(4):1328-34 [8573590.001]
  • [Cites] Carcinogenesis. 1996 Mar;17(3):485-92 [8631134.001]
  • [Cites] Mol Carcinog. 1996 May;16(1):12-9 [8634090.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):366-9 [9012456.001]
  • [Cites] Carcinogenesis. 1997 Jul;18(7):1299-302 [9230271.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Gut. 2000 Sep;47(3):362-5 [10940272.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):827-30 [11221863.001]
  • [Cites] Mol Carcinog. 1999 Feb;24(2):90-8 [10078936.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):493-9 [10480342.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1473-80 [15831531.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1859-65 [16452248.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):463-6 [16477630.001]
  • [Cites] Toxicol Lett. 1994 Jun;72(1-3):175-84 [8202930.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):320-3 [14973087.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):68-72 [10585585.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] Toxicol Pathol. 2000 May-Jun;28(3):375-81 [10862553.001]
  • [Cites] Chem Res Toxicol. 2001 Mar;14(3):295-301 [11258978.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Bioessays. 2002 Mar;24(3):255-66 [11891762.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):168-70 [12107837.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3522S-3525S [12421881.001]
  • [Cites] Mutagenesis. 2002 Nov;17(6):483-7 [12435845.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):595-603 [12663523.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):625-35 [12727789.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):281-6 [15140540.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1243-7 [14963016.001]
  • [Cites] Biochimie. 1982 Aug-Sep;64(8-9):769-73 [6814526.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):196-200 [6690035.001]
  • [Cites] EMBO J. 1982;1(2):211-6 [7188181.001]
  • [Cites] Carcinogenesis. 1986 May;7(5):745-9 [3698202.001]
  • [Cites] Carcinogenesis. 1987 Jan;8(1):91-5 [3802398.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):624-30 [1991846.001]
  • [Cites] Br J Cancer. 1991 Jul;64(1):59-63 [1854628.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1727-31 [1516027.001]
  • [CommentIn] Gut. 2007 Mar;56(3):318-20 [17339242.001]
  • (PMID = 16891355.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / SSPN protein, human; 578-76-7 / 7-methylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Other-IDs] NLM/ PMC1856833
  •  go-up   go-down


43. Madea B, Saukko P, Oliva A, Musshoff F: Molecular pathology in forensic medicine--Introduction. Forensic Sci Int; 2010 Dec 15;203(1-3):3-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Algorithms. Biopsy. Blood Stains. Body Fluids. Brain / metabolism. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Communicable Diseases / diagnosis. Communicable Diseases / genetics. Corpse Dismemberment. DNA Fingerprinting. DNA, Bacterial / genetics. DNA, Viral / genetics. Death, Sudden, Cardiac. Female. Genetic Predisposition to Disease. Humans. Loss of Heterozygosity. Lung Neoplasms / genetics. Lung Neoplasms / pathology. MicroRNAs / metabolism. Mutation. Pharmacogenetics. Physician's Role. Poisoning / metabolism. Polymerase Chain Reaction. Postmortem Changes. RNA / genetics. RNA Stability. RNA, Messenger / metabolism. Receptors, Opioid, mu / genetics. Receptors, Opioid, mu / metabolism. Tandem Repeat Sequences. Wounds and Injuries / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20728291.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Viral; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / Receptors, Opioid, mu; 63231-63-0 / RNA
  •  go-up   go-down


44. Meyer SE, Waltz SE, Goss KH: The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice. Mol Carcinog; 2009 Nov;48(11):995-1004
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):229-38 [11082293.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):424-9 [11281194.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):155-9 [11381263.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5010-5 [11431334.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] J Clin Invest. 2001 Aug;108(4):567-76 [11518730.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8357-60 [11731407.001]
  • [Cites] Genome Res. 2002 Jan;12(1):88-97 [11779834.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):31-41 [12049812.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2051-3 [12242442.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38104-10 [12177064.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1053-60 [12395314.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):186-97 [12527888.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Feb;3(1):31-40 [12570659.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1291-300 [12807733.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1517-26 [1541640.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]
  • [Cites] Int J Oncol. 1999 Oct;15(4):709-14 [10493952.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8464-74 [15378025.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):27-36 [15447977.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):167-72 [9334837.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1087-9 [9515784.001]
  • [Cites] Carcinogenesis. 1998 Apr;19(4):543-9 [9600336.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):437-53 [9659576.001]
  • [Cites] Genes Funct. 1997 Feb;1(1):69-83 [9680329.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):629-35 [9808534.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1399-405 [10188882.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):479-88 [15531916.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1285-93 [15735014.001]
  • [Cites] Ann Surg Oncol. 2005 Apr;12(4):273-81 [15827676.001]
  • [Cites] Acta Pharmacol Sin. 2006 Jun;27(6):641-50 [16723080.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):710-5 [16863504.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8430-8 [16951153.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9162-70 [16982759.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11967-74 [17178895.001]
  • [Cites] Genetics. 2007 Jun;176(2):1237-44 [17435219.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6075-82 [17616662.001]
  • [Cites] Future Oncol. 2007 Aug;3(4):441-8 [17661719.001]
  • [Cites] J Pathol. 2007 Dec;213(4):402-11 [17955509.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6680-7 [18701492.001]
  • [Cites] Oncogene. 1993 May;8(5):1195-202 [8386824.001]
  • [Cites] Hum Mol Genet. 1992 Sep;1(6):387-90 [1338760.001]
  • [Cites] J Cell Biol. 1993 Nov;123(4):877-93 [8227147.001]
  • [Cites] Biochim Biophys Acta. 1993 Dec 23;1155(3):357-71 [8268192.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4 [7576992.001]
  • [Cites] Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):433-51 [8776001.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1134-40 [8831610.001]
  • [Cites] EMBO J. 1996 Nov 1;15(21):5866-75 [8918464.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Scand J Gastroenterol. 2000 May;35(5):534-9 [10868458.001]
  • (PMID = 19452510.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA059268; United States / NCI NIH HHS / CA / R01 CA125379; United States / NCI NIH HHS / CA / CA 100002; United States / NCI NIH HHS / CA / R01 CA100002; United States / NCI NIH HHS / CA / T32 CA 59268
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ NIHMS600186; NLM/ PMC4102426
  •  go-up   go-down


45. National Toxicology Program: Toxicology and carcinogenesis studies of transplacental AZT (Cas No. 30516-87-1) in Swiss (CD-1®) mice (in utero studies). Natl Toxicol Program Tech Rep Ser; 2006 Jun;(522):1-184
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of alveolar/bronchiolar carcinoma and of adenoma or carcinoma (combined) in 200 and 300 mg/kg males were significantly greater than those in the vehicle controls.
  • The incidences of histiocytic cellular infiltration of the lung in 200 and 300 mg/kg males were significantly increased.

  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160102.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


46. Liu J, Waalkes MP: Liver is a target of arsenic carcinogenesis. Toxicol Sci; 2008 Sep;105(1):24-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inorganic arsenic is clearly a human carcinogen causing tumors of the skin, lung, urinary bladder, and possibly liver (IARC, 2004).
  • Recent work in mice clearly shows that exposure to inorganic arsenic during gestation induces tumors, including hepatocellular adenoma and carcinoma, in offspring when they reach adulthood.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] Int J Clin Pharmacol Res. 1988;8(2):117-22 [3378853.001]
  • [Cites] Am J Epidemiol. 1989 Dec;130(6):1123-32 [2589305.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5470-4 [2386951.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):366-76 [15276416.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(12):1255-63 [15345372.001]
  • [Cites] J Toxicol Environ Health A. 2004 Oct 8;67(19):1491-500 [15371225.001]
  • [Cites] Gut. 1979 May;20(5):378-84 [468068.001]
  • [Cites] J Hepatol. 1990 Jul;11(1):80-5 [2398270.001]
  • [Cites] Carcinogenesis. 2004 Mar;25(3):413-7 [14633664.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Toxicol Lett. 1983 Feb;15(2-3):105-8 [6829033.001]
  • [Cites] Arch Toxicol. 1984 Sep;55(3):151-4 [6497648.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5895-9 [4053060.001]
  • [Cites] Br J Cancer. 1986 Mar;53(3):399-405 [3964542.001]
  • [Cites] Lancet. 1988 Feb 20;1(8582):414-5 [2893213.001]
  • [Cites] Environ Health Perspect. 1992 Jul;97:259-67 [1396465.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Am J Epidemiol. 1995 Feb 1;141(3):198-209 [7840093.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1271-6 [7882321.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1995 Oct;16(5):289-91 [8706097.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):263-77 [9219564.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10907-12 [9380733.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):561-9 [9758107.001]
  • [Cites] Environ Health Perspect. 1999 May;107(5):359-65 [10210691.001]
  • [Cites] Arch Environ Health. 1999 May-Jun;54(3):186-93 [10444040.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:269-477 [15645578.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 7;206(2):169-75 [15967205.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1193-8 [16882524.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305 [16712894.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Nov 1;216(3):407-15 [16876216.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jan 5;352(1):188-92 [17107663.001]
  • [Cites] Hepatology. 2007 Jan;45(1):205-12 [17187425.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 May 1;220(3):284-91 [17350061.001]
  • [Cites] Toxicology. 2007 Jul 1;236(1-2):7-15 [17451858.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):295-305 [17481689.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):271-80 [17306315.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):365-73 [17397889.001]
  • [Cites] Int Arch Occup Environ Health. 2007 Oct;81(1):9-17 [17387503.001]
  • [Cites] Am J Public Health. 2004 May;94(5):741-4 [15117692.001]
  • [Cites] Indian J Gastroenterol. 1999 Oct-Nov;18(4):152-5 [10531716.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35 [10873715.001]
  • [Cites] Environ Health Perspect. 2000 Jul;108(7):655-61 [10903620.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):135-45 [10963625.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):185-92 [11134558.001]
  • [Cites] Mol Carcinog. 2001 Feb;30(2):79-87 [11241755.001]
  • [Cites] Toxicol Sci. 2001 Jun;61(2):314-20 [11353140.001]
  • [Cites] Mol Pharmacol. 2001 Aug;60(2):302-9 [11455017.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Sep 15;175(3):260-8 [11559025.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):151-9 [11756236.001]
  • [Cites] Environ Health Perspect. 2002 Feb;110(2):119-22 [11836136.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):777-85 [12016150.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):136-9 [12115560.001]
  • [Cites] Toxicol Sci. 2002 Nov;70(1):13-9 [12388830.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:883-6 [12426152.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] J Hepatol. 2003 Sep;39(3):383-8 [12927924.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1827-35 [12919961.001]
  • [Cites] Toxicology. 2003 Nov 15;193(1-2):161-9 [14599775.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • (PMID = 18566022.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; N712M78A8G / Arsenic
  • [Number-of-references] 86
  • [Other-IDs] NLM/ PMC2734307
  •  go-up   go-down


47. Millen AE, Subar AF, Graubard BI, Peters U, Hayes RB, Weissfeld JL, Yokochi LA, Ziegler RG, PLCO Cancer Screening Trial Project Team: Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am J Clin Nutr; 2007 Dec;86(6):1754-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial.
  • BACKGROUND: Research on the association between fruit and vegetable intake and risk of colorectal adenoma is inconclusive.
  • OBJECTIVE: We studied whether intake of fruit, vegetables, or their subgroups is associated with a lower risk of prevalent colorectal adenoma.
  • DESIGN: In men and women (aged 55-74 y) who were screened for colorectal cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (1993-2001), we compared 3,057 cases with at least one prevalent histologically verified adenoma of the distal large bowel with 29,413 control subjects.
  • RESULTS: Risk of distal adenoma was significantly lower among subjects in high (approximately 5.7 ps/d) versus low (approximately 1.2 ps/d) quintiles of total fruit intake (OR: 0.75; 95% CI: 0.66, 0.86, P for trend <0.001), which was not completely explained by dietary folate or fiber intake.
  • Inverse associations between adenoma and total fruit intake were observed regardless of adenoma histopathology and multiplicity.
  • However, the protective effect was seen only for colon and not rectal adenoma.
  • Total vegetable intake was not significantly associated with reduced risk of adenoma.
  • ORs for colorectal adenoma among persons with high versus low intakes of deep-yellow vegetables, dark-green vegetables, and onions and garlic were significantly related to lower risk of adenoma, although the P for trend for dark-green vegetables was not significant.
  • CONCLUSION: Diets rich in fruit and deep-yellow vegetables, dark-green vegetables, and onions and garlic are modestly associated with reduced risk of colorectal adenoma, a precursor of colorectal cancer.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Fruit. Vegetables

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065596.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


48. Molino C, Fabbian F, Russo G, Cantelli S, Bortot A, Galdi A, Catizone L: [MEN type 1 and chronic renal failure: a rarely reported association]. G Ital Nefrol; 2007 Jan-Feb;24(1):79-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 70-year-old Caucasian female patient had a history of primitive hyperparathyroidism, prolactinoma, glucagonoma, adrenal adenoma and pulmonary neuroendocrine neoplasia.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342698.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Kaspareit J, Friderichs-Gromoll S, Buse E, Habermann G: Spontaneous neoplasms observed in cynomolgus monkeys (Macaca fascicularis) during a 15-year period. Exp Toxicol Pathol; 2007 Nov;59(3-4):163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the tumors (22) in the cynomolgus monkeys were seen in endocrine organs (adrenal cortical adenoma, adrenal hemangioma, C-cell carcinoma, follicular adenoma), respiratory system (nasal cavity adenoma, pulmonary squamous cell carcinoma, bronchio-alveolar carcinoma, bronchiolar papilloma, chondromatous hamartoma) and female genital system (uterine polyp, uterine adenoma, uterine leiomyoma and teratoma of the ovary).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869495.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Minato H, Kaji S, Kinoshita E, Kurose N, Nojima T, Kohno M, Konuma K, Ikawa H: Solitary intrapulmonary cystic lymphangioma in an infant: a case report with literature review. Pathol Res Pract; 2010 Dec 15;206(12):851-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphangioma rarely presents as a solitary pulmonary lesion.
  • Chest X-ray showed a large cyst in the right lung.
  • Differential diagnoses included lobar or interstitial emphysema, bronchogenic cyst, congenital pulmonary airway malformation and alveolar adenoma.
  • A review of the literature found only 15 cases of solitary pulmonary lymphangioma.
  • In younger patients, the lesions tend to occupy more of the lung.
  • [MeSH-major] Bronchogenic Cyst / diagnosis. Lung Neoplasms / diagnosis. Lymphangioma, Cystic / diagnosis. Pulmonary Emphysema / diagnosis

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20952134.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / monoclonal antibody D2-40; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


51. Mirallié E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodéré F: Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery; 2007 Dec;142(6):952-8; discussion 952-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty patients were operated on, 19 had neck surgery with mediastinal lymph node dissection (1 case) and lung resection (1 case), and 1 underwent lung resection.
  • [MeSH-minor] Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cell Differentiation. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Patient Selection. Prospective Studies. Radiopharmaceuticals. Thyroglobulin / blood. Thyroidectomy

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063081.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


52. Müller-Brüsselbach S, Ebrahimsade S, Jäkel J, Eckhardt J, Rapp UR, Peters JM, Moll R, Müller R: Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene. Int J Oncol; 2007 Sep;31(3):607-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene.
  • In the present study, we have addressed the role of PPARbeta and PPARgamma in lung tumorigenesis in a transgenic mouse model of RAF-induced lung adenoma using two different strategies: i) crossing with PPARbeta null mice, and ii) chronic treatment with the PPARgamma agonist rosiglitazone.
  • These observations indicate i) that RAF-induced lung tumorigenesis is attenuated in mice with a disrupted Pparb gene, and ii) that chronic PPARgamma activation does not affect lung adenoma growth.
  • [MeSH-major] Adenoma / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. PPAR delta / genetics. PPAR-beta / genetics. Proto-Oncogene Proteins c-raf / genetics


53. Sharma S, Gao P, Steele VE: The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model. Carcinogenesis; 2006 Aug;27(8):1721-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model.
  • This study explored the efficacy of oltipraz, a dithiolthione to prevent lung cancer by delivering it directly to the lung as inhaled particulates to obtain maximum efficacy with no toxicity.
  • Two exposure regimens were used to compare the efficacies of early (Regimen-A) versus late (Regimen-B) intervention in prevention of lung tumorigenesis in A/J mice.
  • The spontaneous tumors were few in untreated A/J mice (0.7 tumors/lung), whereas there was an average of 16.5 tumors per lung in the B[a]P group (20-fold induction).
  • Evaluation of lung tumor multiplicity following exposure to oltipraz showed that oltipraz inhibited the tumor development in a dose-dependent manner (10-100 mg/m(3)) with inhibition ranging from 37 to 53% in Regimen A and 51% in Regimen B, when compared with the B[a]P group.
  • The data from this study show that oltipraz is an effective agent for lung cancer prevention, when it is delivered directly to the target tissue as aerosolized particulates.
  • [MeSH-major] Adenoma / prevention & control. Anticarcinogenic Agents / therapeutic use. Benzo(a)pyrene / toxicity. Lung Neoplasms / prevention & control. Pyrazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632869.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25112
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Pyrazines; 3417WMA06D / Benzo(a)pyrene; 6N510JUL1Y / oltipraz
  •  go-up   go-down


54. Bermejo JL, Eng C, Hemminki K: Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology; 2005 Dec;129(6):1889-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Families that fulfilled the Bethesda criteria showed increased risks of cancer in the colorectum, endometrium, small bowel, ovary, stomach, bile ducts, renal pelvis, and ureter; members of Bethesda criteria families were at decreased risks of lung and cervical cancers.
  • CONCLUSIONS: Most malignancies in the classified families reflect typical features of HNPCC (association with subsequent malignancies, accelerated adenoma-carcinoma sequence, and better survival).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344057.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A; 2007 Jun 19;104(25):10625-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-VEGF-A monoclonal antibodies, in combination with chemotherapy, result in a survival benefit in patients with metastatic colorectal and non-small cell lung cancer, but little is known regarding the impact of anti-VEGF-A therapy on benign or premalignant tumors.
  • The Apc+/min mice have been widely used as a model recapitulating early intestinal adenoma formation.
  • Short-term (3 or 6 weeks) treatment with anti-VEGF-A Mab G6-31 resulted in a nearly complete suppression of adenoma growth throughout the small intestine.
  • These results establish that inhibition of VEGF-A signaling is sufficient for tumor growth cessation and confers a long-term survival benefit in an intestinal adenoma model.
  • [MeSH-minor] Adenoma / blood supply. Adenoma / genetics. Adenoma / immunology. Adenoma / therapy. Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Gene Deletion. In Situ Hybridization. Intestinal Neoplasms / blood supply. Intestinal Neoplasms / genetics. Intestinal Neoplasms / immunology. Intestinal Neoplasms / therapy. Mice. Mice, Inbred C57BL. Signal Transduction / immunology. Survival Analysis. Time Factors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Cancer Lett. 2002 Jan 25;175(2):157-63 [11741743.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Dev Dyn. 2002 May;224(1):90-102 [11984877.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1351-9 [12151354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):1721-7 [14521839.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Exp Med. 1972 Aug 1;136(2):261-76 [5043412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8488-92 [3909146.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Development. 1992 Jul;115(3):717-28 [1425351.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1789-97 [7535799.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4267-73 [9331087.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):1-10 [9537593.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):51-8 [9934849.001]
  • [Cites] Development. 1999 Mar;126(6):1149-59 [10021335.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1710-7 [16685275.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2133-9 [16782971.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83 [17360669.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • (PMID = 17553957.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1888576
  •  go-up   go-down


56. Ilhan HD, Oner FH, Sarioglu S, Lebe B, Saatci AO: Bilateral choroidal metastasis from carcinoma ex pleomorphic adenoma of the parotid gland. Clin Exp Ophthalmol; 2005 Feb;33(1):70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral choroidal metastasis from carcinoma ex pleomorphic adenoma of the parotid gland.
  • The histological, clinical and angiographic findings are reported of a 34-year-old man with bilateral visual loss who had left parotidectomy with subsequent radiotherapy due to carcinoma ex pleomorphic adenoma of the parotid gland 1 year before.
  • At the time of ocular diagnosis, lung, pleura and pharynx metastases had recently been revealed.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma, Pleomorphic / pathology. Choroid Neoplasms / secondary. Parotid Neoplasms / pathology

  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670083.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Coloring Agents; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


57. Yener S, Ertilav S, Secil M, Akinci B, Demir T, Comlekci A, Yesil S: Natural course of benign adrenal incidentalomas in subjects with extra-adrenal malignancy. Endocrine; 2009 Aug;36(1):135-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / epidemiology. Adrenal Cortex Neoplasms / epidemiology. Cushing Syndrome / epidemiology. Neoplasms / epidemiology. Pheochromocytoma / epidemiology
  • [MeSH-minor] Adult. Aged. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Renal Cell / epidemiology. Disease Progression. Female. Follow-Up Studies. Humans. Incidental Findings. Kidney Neoplasms / epidemiology. Lung Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Middle Aged. Pancreatic Neoplasms / epidemiology. Prevalence. Registries

  • MedlinePlus Health Information. consumer health - Benign Tumors.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Mar;129(3):291-6 [8129606.001]
  • [Cites] J Endocrinol Invest. 2007 Sep;30(8):647-52 [17923795.001]
  • [Cites] Surgery. 1991 Dec;110(6):1014-21 [1745970.001]
  • [Cites] Surgery. 1998 Dec;124(6):1115-22 [9854592.001]
  • [Cites] Endocrinology. 1992 Mar;130(3):1394-400 [1537299.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] JAMA. 1982 Aug 13;248(6):701-4 [7097921.001]
  • [Cites] J Neuroendocrinol. 2008 Jun;20(6):880-4 [18601712.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):34-46 [18043254.001]
  • [Cites] N Engl J Med. 2007 Feb 8;356(6):601-10 [17287480.001]
  • [Cites] Front Neuroendocrinol. 2003 Jul;24(3):151-80 [14596810.001]
  • [Cites] Eur J Endocrinol. 2003 Oct;149(4):273-85 [14514341.001]
  • [Cites] AJR Am J Roentgenol. 2008 May;190(5):1163-8 [18430826.001]
  • [Cites] Surg Gynecol Obstet. 1986 Sep;163(3):203-8 [3750174.001]
  • [Cites] AJR Am J Roentgenol. 1982 Jul;139(1):81-5 [6979870.001]
  • [Cites] Surgery. 2001 Dec;130(6):1060-7 [11742339.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):423-39, x [15850851.001]
  • [Cites] Br J Pharmacol. 1995 Nov;116(5):2417-24 [8581278.001]
  • [Cites] Am J Surg. 1985 Jun;149(6):783-8 [4014556.001]
  • (PMID = 19381885.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Sugi O, Kimata N, Miwa N, Otsubo S, Nitta K, Akiba T: Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas. NDT Plus; 2010 Feb;3(1):60-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas.
  • Computed tomography scan indicated the presence of multiple ectopic lung nodules and 26 nodules were surgically removed from the left lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25984040.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4421561
  • [Keywords] NOTNLM ; cinacalcet / ectopic parathyroid adenoma / haemodialysis / hyperparathyroidism
  •  go-up   go-down


59. Licchesi JD, Westra WH, Hooker CM, Herman JG: Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res; 2008 May 1;14(9):2570-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung.
  • The recognition of an early form of glandular neoplasia termed atypical adenomatous hyperplasia (AAH), a precursor lesion from which lung adenocarcinomas arise, provides an opportunity for characterizing early epigenetic alterations involved in lung tumorigenesis.
  • EXPERIMENTAL DESIGN: We evaluated AAHs, adjacent normal lung tissue, and synchronous lung adenocarcinomas for promoter hypermethylation of genes implicated in lung tumorigenesis (p16, TIMP3, DAPK, MGMT, RARbeta, RASSF1A, and hTERT).
  • CONCLUSION: This study shows epigenetic progression in the earliest stages of glandular neoplasia of the lung and has implications for early lung cancer detection.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. DNA Methylation. Genes, Neoplasm. Lung Neoplasms / genetics. Precancerous Conditions / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Epigenesis, Genetic. Humans. Hyperplasia. Lung / metabolism. Lung / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451218.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA058184
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


60. National Toxicology Program: Toxicology and carcinogenesis studies of dibromoacetic acid (Cas No. 631-64-1) in F344/N rats and B6C3F1 mice (drinking water studies). Natl Toxicol Program Tech Rep Ser; 2007 Apr;(537):1-320
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of multiple hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) were significantly increased in all exposed groups of males and in 500 and 1,000 mg/L females.
  • The incidences of alveolar/bronchiolar adenoma occurred with positive trends in males and females, and the incidence in 500 mg/L male mice was significantly greater than that in controls.
  • Increased incidences of lung neoplasms in male mice were also considered to be exposure related.
  • The slight increased incidence of lung neoplasms in female mice may have been related to dibromoacetic acid exposure.
  • [MeSH-minor] Administration, Oral. Animals. Body Weight / drug effects. CHO Cells. Cricetinae. Cricetulus. Drug-Induced Liver Injury / etiology. Drug-Induced Liver Injury / pathology. Female. Kidney Diseases / chemically induced. Kidney Diseases / pathology. Liver / drug effects. Liver / pathology. Liver Neoplasms / chemically induced. Liver Neoplasms / pathology. Lung Neoplasms / chemically induced. Lung Neoplasms / pathology. Male. Mesothelioma / chemically induced. Mesothelioma / secondary. Mice. Mice, Inbred Strains. Micronuclei, Chromosome-Defective / chemically induced. Organ Size / drug effects. Rats. Rats, Inbred F344. Salmonella typhimurium / drug effects. Salmonella typhimurium / genetics. Testis / drug effects. Testis / pathology. Water Supply

  • Hazardous Substances Data Bank. DIBROMOACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554398.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / Carcinogens; 0 / Environmental Pollutants; 0 / Mutagens; 631-64-1 / dibromoacetic acid
  •  go-up   go-down


61. Alexander CL, Urbanski SJ, Hilsden R, Rabin H, MacNaughton WK, Beck PL: The risk of gastrointestinal malignancies in cystic fibrosis: case report of a patient with a near obstructing villous adenoma found on colon cancer screening and Barrett's esophagus. J Cyst Fibros; 2008 Jan;7(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of gastrointestinal malignancies in cystic fibrosis: case report of a patient with a near obstructing villous adenoma found on colon cancer screening and Barrett's esophagus.
  • Although the overall cancer risk for CF patients does not appear to be increased there is a marked increased risk of gastrointestinal malignancies especially in the post lung transplant population.
  • We present a 39 year old male CF patient that underwent a colonoscopy for colon cancer screening and a large, near obstructing, villous adenoma of his ileum was found.
  • [MeSH-major] Adenoma, Villous / complications. Barrett Esophagus / complications. Cystic Fibrosis / complications. Ileal Neoplasms / complications


62. Peters U, Chatterjee N, Church TR, Mayo C, Sturup S, Foster CB, Schatzkin A, Hayes RB: High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):315-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program.
  • METHODS: We studied the association of serum selenium and advanced colorectal adenoma, a cancer precursor, in 758 cases and 767 sex- and race-matched controls, randomly selected from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  • Cases had at least one verified advanced adenoma (> or = 1 cm or villous elements, or high-grade dysplasia) of the distal colon, and controls had a negative sigmoidoscopy.
  • The inverse association between serum selenium and advanced colorectal adenoma was significant among recent smokers (OR, 0.53; 95% CI, 0.27-1.01 for highest versus lowest tertile; P(trend) = 0.008).
  • Serum selenium was unrelated to adenoma risk in nonsmokers and former smokers who quit smoking > or = 10 years ago.
  • CONCLUSION: Selenium may reduce the risk of developing advanced colorectal adenoma, particularly among the high-risk group of recent smokers.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Selenium / blood. Smoking / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492922.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] H6241UJ22B / Selenium
  •  go-up   go-down


63. Rajput R, Bhansali A, Dutta P, Gupta SK, Radotra BD, Bhadada S: Pituitary metastasis masquerading as non-functioning pituitary adenoma in a woman with adenocarcinoma lung. Pituitary; 2006;9(2):155-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary metastasis masquerading as non-functioning pituitary adenoma in a woman with adenocarcinoma lung.
  • However, pituitary metastasis manifesting as bitemporal hemianopia as a presenting manifestation in a patient with silent adenocarcinoma of the lung, that too in a women, is quite uncommon.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Lung Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1970 Sep;26(3):656-9 [5272295.001]
  • [Cites] Neurosurgery. 1981 Apr;8(4):477-80 [7242903.001]
  • [Cites] Br J Neurosurg. 1989;3(1):71-9 [2789715.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):69-73 [9647174.001]
  • [Cites] Neurology. 1981 Aug;31(8):998-1002 [7196526.001]
  • [Cites] J Neurosurg Sci. 1992 Jan-Mar;36(1):51-4 [1323647.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):574-80 [14764764.001]
  • [Cites] Presse Med. 1999 Oct 2;28(29):1567-71 [10544705.001]
  • [Cites] Neurochirurgia (Stuttg). 1990 Jul;33(4):127-31 [2203980.001]
  • (PMID = 16832588.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M: Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene; 2006 Aug 31;25(39):5467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.
  • About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases.
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / pathology. Amino Acid Substitution. Animals. Cell Differentiation. Humans. Mice. Mice, Transgenic. Neoplasm Invasiveness


65. Leonetti JP, Marzo SJ, Petruzzelli GJ, Herr B: Recurrent pleomorphic adenoma of the parotid gland. Otolaryngol Head Neck Surg; 2005 Sep;133(3):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pleomorphic adenoma of the parotid gland.
  • OBJECTIVES: To assess the long-term results in the management of 42 patients with recurrent pleomorphic adenoma of the parotid gland.
  • STUDY DESIGN: A retrospective analysis of 42 patients who underwent parotidectomy for recurrent pleomorphic adenoma was performed to study presenting clinicoradiographic features, surgical technique, facial nerve management, and the long-term risk of recurrence.
  • The 2 patients with malignant transformation died of disseminated lung and bone metastasis.
  • Total parotidectomy or subtotal petrosectomy with facial nerve resection in selected cases may reduce the risk of multiple episodes of pleomorphic adenoma recurrence.
  • Two of 42 patients were found to have carcinoma ex-pleomorphic adenoma, both of these patients underwent prior radiotherapy, and both died of metastatic disease.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Parotid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143173.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Kosacka M, Wojtala R, Piesiak P, Passowicz-Muszyńska E, Jankowska R: [A case of kappa L-chain primary nodular lung amyloidosis]. Pol Merkur Lekarski; 2008 Dec;25(150):516-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of kappa L-chain primary nodular lung amyloidosis].
  • We report a case of kappa L-chain primary lung amyloidosis.
  • After the quadrantectomy the breast tumor has been diagnosed as adenoma.
  • The diagnosis of pulmonary amyloidosis was established by an open lung biopsy.
  • The case illustrates the problems with diagnosis of multiple solitary nodules and the long and relatively benign course of primary pulmonary amyloidosis.
  • [MeSH-major] Amyloid / metabolism. Amyloidosis / diagnosis. Amyloidosis / metabolism. Immunoglobulin kappa-Chains / metabolism. Solitary Pulmonary Nodule / diagnosis. Solitary Pulmonary Nodule / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Biopsy. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205385.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Amyloid; 0 / Biomarkers; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


67. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathology of the salivary gland tumors were mucoepidermoid carcinoma (10), adenoid cystic carcinoma (1) , and pleomorphic adenoma (1).
  • Eleven patients were alive with no evidence of disease at last follow-up, and 1 patient was alive with clinical evidence of pulmonary metastasis.
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


68. Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, Larsson C: Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS One; 2010;5(3):e9472
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypermethylation of p16(INK4A) was demonstrated in a single adenoma, whereas RAR-beta hypermethylation was not observed in any sample.
  • [MeSH-minor] Adenoma / metabolism. CpG Islands. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Epigenesis, Genetic. Gene Expression Profiling. Genotype. Humans. Long Interspersed Nucleotide Elements. Parathyroid Glands / metabolism. Receptors, Retinoic Acid / metabolism

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3663-7 [8855819.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2627-30 [9709922.001]
  • [Cites] Kidney Int. 1999 Apr;55(4):1375-83 [10201002.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3775-80 [10523029.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):37-43 [15375009.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):612-20 [15632063.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5052-60 [15923622.001]
  • [Cites] Cell. 2006 Apr 21;125(2):327-41 [16630820.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):509-23 [16728578.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):109-16 [16893590.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):338-44 [17047023.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):125-34 [17395981.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):501-12 [17639063.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] World J Gastroenterol. 2008 Jan 28;14(4):595-600 [18203293.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2551-9 [18451216.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):609-21 [18509008.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4038-44 [18593979.001]
  • [Cites] Int J Oncol. 2008 Oct;33(4):861-9 [18813801.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1954-6 [18385753.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1735-42 [18841156.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17420-5 [18987311.001]
  • [Cites] Exp Mol Pathol. 2008 Dec;85(3):201-6 [18977219.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8 [19033568.001]
  • [Cites] Mol Cancer Res. 2008 Dec;6(12):1894-907 [19074834.001]
  • [Cites] Int J Cancer. 2009 Mar 1;124(5):1122-32 [19058182.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):481-92 [19148484.001]
  • [Cites] Prostate. 2009 Nov 1;69(15):1643-50 [19623543.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1998-2004 [11448917.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3663-6 [12097272.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):676-80 [12434154.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4010-4 [15217932.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):643-5 [1310068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4452-6 [1316610.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1317-21 [7962323.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):1736-9 [8626826.001]
  • [Cites] Genomics. 1997 Aug 15;44(1):94-100 [9286704.001]
  • (PMID = 20208994.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2830427
  •  go-up   go-down


69. Rindi G, Licini L, Necchi V, Bottarelli L, Campanini N, Azzoni C, Favret M, Giordano G, D'Amato F, Brancia C, Solcia E, Ferri GL: Peptide products of the neurotrophin-inducible gene vgf are produced in human neuroendocrine cells from early development and increase in hyperplasia and neoplasia. J Clin Endocrinol Metab; 2007 Jul;92(7):2811-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Developing and normal adult endocrine cells, hyperplastic endocrine lesions (thyroid, parathyroid, lung, and stomach), and 120 tumors (102 endocrine) were studied.
  • RESULTS: proVGF fragments were revealed in developing pituitary, gut, pancreas, and adrenal medulla from 10 gestational weeks, in normal adult pituitary and adrenal medulla, pancreatic glucagon, and insulin cells and gut serotonin cells, in hyperplastic thyroid calcitonin cells, lung P cells, gastric enterochromaffin-like cells, and gastrin cells, and in 88 of 102 endocrine tumors.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Endocrine Gland Neoplasms / metabolism. Endocrine Gland Neoplasms / pathology. Nerve Growth Factors / metabolism

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440014.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / VGF protein, human
  •  go-up   go-down


70. Kassie F, Kalscheuer S, Matise I, Ma L, Melkamu T, Upadhyaya P, Hecht SS: Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice. Carcinogenesis; 2010 Feb;31(2):239-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J mice.
  • In previous studies, we reported that indole-3-carbinol (I3C) and myo-inositol (MI) inhibit lung adenoma induced by tobacco smoke carcinogens in A/J mice.
  • In this paper, we extended our work and examined the effects of I3C (70 or 30 micromol/g diet) and MI (56 micromol/g diet) against vinyl carbamate (VC)-induced lung adenocarcinoma by administering the agents from 1 week after the second of two injections of VC until termination of the study at week 18.
  • The higher dose of I3C decreased multiplicities of tumors on the surface of the lung (26%, P = 0.0005), carcinoma incidence (38%), multiplicity (67%, P < 0.0001) and size (complete abolition of carcinoma with an area of >1.0 cm(2)) as well as adenoma with cellular pleomorphism (46%, P < 0.0001).
  • MI decreased multiplicities of pulmonary surface tumors (20%, P = 0.0005), adenoma with cellular pleomorphism (40%, P < 0.0001) and lung adenoma (52%, P < 0.0001) and the proportion of the biggest carcinoma (carcinoma with an area of >1.0 cm(2), P < 0.05).
  • Immunoblot analyses of lung tissues for potential target identification showed that I3C (70 micromol/g diet) inhibits IkappaBalpha degradation, nuclear factor-kappaB activation, expression of cyclooxygenase-2, phospho-Akt and fatty acid synthase (FAS) and activates caspase-3 and poly ADP ribose polymerase cleavage.
  • Our data show that I3C and MI inhibit lung carcinoma and provide a basis for future evaluation of these compounds in clinical trials as chemopreventive agents for current and former smokers.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6853-66 [10602461.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5592-600 [19531648.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):757-72 [11195469.001]
  • [Cites] Cancer Lett. 2001 Jun 10;167(1):1-6 [11323092.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2927-36 [11420705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):642-6 [11830512.001]
  • [Cites] Carcinogenesis. 2002 Sep;23(9):1455-61 [12189187.001]
  • [Cites] Chest. 2003 Nov;124(5):1828-33 [14605056.001]
  • [Cites] Carcinogenesis. 2004 Feb;25(2):197-201 [14578161.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):45-52 [15179623.001]
  • [Cites] Nutr Cancer. 2004;48(1):84-94 [15203382.001]
  • [Cites] Prostate. 2004 Oct 1;61(2):153-60 [15305338.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2613-7 [2328487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9543-7 [1658785.001]
  • [Cites] Carcinogenesis. 1993 Sep;14(9):1975-7 [8403228.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5132-5 [8912846.001]
  • [Cites] Anticancer Res. 1996 Sep-Oct;16(5A):2709-12 [8917375.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):139-45 [9934861.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2053-9 [15240509.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:236-43 [15574364.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1137-41 [15797040.001]
  • [Cites] Blood. 2005 Jul 15;106(2):641-9 [15811958.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8548-57 [16166336.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):541-50 [16199440.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):717-28 [16332727.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4952-60 [16651453.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31 [16896044.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2116-23 [16704990.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2747-56 [17121921.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11494-501 [17145898.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3310-9 [17409440.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6502-11 [17616712.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2757-65 [17913854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7139-45 [18056164.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2458-64 [18413838.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Sep;1(4):285-97 [19138972.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Dec;1(7):568-76 [19139007.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):519-32 [19318631.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):370-6 [19336734.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5764-71 [11126363.001]
  • (PMID = 19625346.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-102502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Indoles; 12001-76-2 / Vitamin B Complex; 3IN71E75Z5 / Urethane; 4L6452S749 / Inositol; 7Y2431GOM5 / vinyl carbamate; C11E72455F / indole-3-carbinol; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2812566
  •  go-up   go-down


71. Kobayashi M, Nakano K, Nukui A, Goto K, Morita T: Bilateral massive renal angiomyolipoma concurrent with oncocytoma in tuberous sclerosis complex associated with pulmonary lymphangioleiomyomatosis. Urology; 2008 Oct;72(4):948.e7-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral massive renal angiomyolipoma concurrent with oncocytoma in tuberous sclerosis complex associated with pulmonary lymphangioleiomyomatosis.
  • We describe a patient with tuberous sclerosis complex and massive bilateral renal angiomyolipomas (AMLs) in association with pulmonary lymphangioleiomatosis, who experienced hemorrhagic shock because of rupture of the left renal AML.
  • This case also represents a rare, but significant, overlap between renal AML, pulmonary lymphangioleiomatosis, and tuberous sclerosis complex.
  • [MeSH-major] Adenoma, Oxyphilic / complications. Angiomyolipoma / complications. Kidney Neoplasms / complications. Lung Neoplasms / complications. Lymphangioleiomyomatosis / complications. Neoplasms, Multiple Primary / complications. Tuberous Sclerosis / complications


72. Petrella F, Rizzo S, Pelosi G, Borri A, Galetta D, Gasparri R, Solli P, Veronesi G, Spaggiari L: Giant alveolar adenoma causing severe dyspnoea. J Thorac Oncol; 2010 Jul;5(7):1088-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant alveolar adenoma causing severe dyspnoea.
  • [MeSH-major] Adenoma / complications. Dyspnea / etiology. Lung Neoplasms / complications. Pulmonary Alveoli / pathology

  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581577.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Takahashi S, Kuwabara K, Sawafuji M, Akiduki S, Ishizaka A: F-18 FDG PET imaging in a patient with granulocyte colony stimulating factor producing pulmonary pleomorphic carcinoma. Clin Nucl Med; 2008 Aug;33(8):555-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET imaging in a patient with granulocyte colony stimulating factor producing pulmonary pleomorphic carcinoma.
  • [MeSH-major] Adenoma, Pleomorphic / blood. Adenoma, Pleomorphic / radionuclide imaging. Bone Marrow Diseases / blood. Bone Marrow Diseases / radionuclide imaging. Fluorodeoxyglucose F18. Granulocyte Colony-Stimulating Factor / blood. Lung Neoplasms / blood. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645378.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


74. Mohr U, Ernst H, Roller M, Pott F: Pulmonary tumor types induced in Wistar rats of the so-called "19-dust study". Exp Toxicol Pathol; 2006 Aug;58(1):13-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary tumor types induced in Wistar rats of the so-called "19-dust study".
  • The incidences of primary lung tumor types histologically diagnosed in 28 groups of Wistar rats of the so-called "19-dust study" are described, the total study having been already presented by Pott and Roller (Carcinogenicity study with nineteen granular dusts in rats.
  • In 579 (58%) lungs of 1002 rats which survived more than 26 weeks after the first instillation of GBP, at least one primary lung tumor type was observed, and in 306 (31%) at least two types.
  • Three benign tumor types were diagnosed in the 579 tumor-bearing rats: bronchiolo-alveolar adenoma in 46%, cystic keratinizing epithelioma in 53%, and non-keratinizing epithelioma in 2.6% of the rats.
  • Numerous lungs with a malignant tumor also showed one or more benign tumor types.
  • In addition, single or multiple metastases from primary tumors of other sites (mainly carcinoma of the uterus) were diagnosed in 14% of the 1002 lungs.
  • [MeSH-major] Adenoma / chemically induced. Air Pollutants / toxicity. Carcinoma / chemically induced. Dust. Lung Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Aluminum oxide .
  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. CARBON .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Exp Toxicol Pathol. 2007 Aug;58(6):407; author reply 409 [17560773.001]
  • (PMID = 16806863.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Aluminum Silicates; 0 / Dust; 15FIX9V2JP / titanium dioxide; 7440-44-0 / Carbon; 7631-86-9 / Silicon Dioxide; D1JT611TNE / Titanium; LMI26O6933 / Aluminum Oxide
  •  go-up   go-down


75. Herszényi L, Farinati F, Cardin R, István G, Molnár LD, Hritz I, De Paoli M, Plebani M, Tulassay Z: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer; 2008;8:194
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma, Villous / genetics. Biomarkers, Tumor / blood. Colorectal Neoplasms / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1458-62 [16552821.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1026-35 [16435385.001]
  • [Cites] Biol Chem. 2006 Aug;387(8):1121-8 [16895483.001]
  • [Cites] BMC Cancer. 2006;6:211 [16916471.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Cancer Sci. 2006 May;97(5):395-9 [16630137.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1675-81 [10547539.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2602-11 [10594855.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):617-23 [11005561.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):624-30 [11274010.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5195-8 [11326694.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2757-64 [11555589.001]
  • [Cites] Int J Cancer. 2002 Oct 20;101(6):545-8 [12237895.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1538-44 [14605576.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):659-64 [14744782.001]
  • [Cites] Cancer Lett. 2004 Mar 8;205(1):97-106 [15036666.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1610-6 [15196548.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5489-92 [6193872.001]
  • [Cites] Gut. 1986 Feb;27(2):117-22 [3949243.001]
  • [Cites] Cancer Res. 1987 Sep 1;47(17):4654-7 [3621160.001]
  • [Cites] Int J Biol Markers. 1988 Apr-Jun;3(2):101-6 [2977396.001]
  • [Cites] Semin Cancer Biol. 1990 Apr;1(2):137-52 [2103490.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s [1884381.001]
  • [Cites] Gut. 1993 Jan;34(1):80-5 [8432457.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1788-93 [8467497.001]
  • [Cites] Cancer Lett. 1993 Jun 15;70(1-2):41-4 [8330299.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:1-12 [1339240.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2900-7 [8187075.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1449-56 [7926508.001]
  • [Cites] Cancer Lett. 1995 Sep 25;96(2):267-75 [7585467.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):367-75 [8625115.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1035-43 [8635120.001]
  • [Cites] Carcinogenesis. 1996 Dec;17(12):2581-7 [9006092.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):843-7 [9149198.001]
  • [Cites] Br J Cancer. 1997;75(12):1793-801 [9192984.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):418-25 [9219730.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1511-6 [9626470.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1346-9 [9823977.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):921-9 [10411440.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1135-42 [10506696.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4147-61 [15736466.001]
  • [Cites] J Cell Sci. 2005 Apr 1;118(Pt 7):1493-503 [15769846.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):676-81 [15841311.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1377-84 [15865094.001]
  • [Cites] Cancer Lett. 2005 Jun 8;223(2):313-22 [15896466.001]
  • [Cites] Scand J Gastroenterol. 2005 Jul;40(7):783-93 [16109653.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):799-803 [16091756.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] J Exp Ther Oncol. 2006;5(3):223-9 [16528972.001]
  • [Cites] Oncol Rep. 2007 Feb;17(2):361-7 [17203175.001]
  • [Cites] World J Gastroenterol. 2007 Feb 7;13(5):676-82 [17278189.001]
  • [Cites] Lung Cancer. 2007 Apr;56(1):43-50 [17207889.001]
  • [Cites] Head Neck. 2007 Apr;29(4):341-50 [17163465.001]
  • [Cites] Crit Rev Clin Lab Sci. 2007;44(2):179-201 [17364692.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] J Cell Biochem. 2006 Apr 15;97(6):1230-40 [16315320.001]
  • (PMID = 18616803.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; EC 3.4.- / Cathepsins; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  • [Other-IDs] NLM/ PMC2474636
  •  go-up   go-down


76. Moody TW: Thymosin alpha1 as a chemopreventive agent in lung and breast cancer. Ann N Y Acad Sci; 2007 Sep;1112:297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymosin alpha1 as a chemopreventive agent in lung and breast cancer.
  • The ability of thymosin alpha1 (Talpha1) to prevent lung and breast cancer was investigated.
  • Lung adenomas developed in A/J mice injected with carcinogens, such as urethane.
  • The lung adenoma number was reduced by 15-45% if animals were daily treated subcutaneously (s.c.) with Talpha1 (0.4 mg/kg).
  • Talpha1 (1 microM) directly inhibited the growth of mouse lung cell lines.
  • These results suggest that Talpha1 may prevent mouse lung carcinogenesis because it directly inhibits the growth of lung cancer cells.
  • These results indicate that Talpha1 is a chemopreventive agent in animal models for lung and breast carcinogenesis.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Lung Neoplasms / prevention & control. Mammary Neoplasms, Animal / prevention & control. Thymosin / analogs & derivatives
  • [MeSH-minor] Adenoma / prevention & control. Animals. Female. Mice. Mice, Inbred A. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17567944.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / thymalfasin; 61512-21-8 / Thymosin
  •  go-up   go-down


77. Witschi H: The complexities of an apparently simple lung tumor model: The A/J mouse. Exp Toxicol Pathol; 2005 Jul;57 Suppl 1:171-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The complexities of an apparently simple lung tumor model: The A/J mouse.
  • Lung surface tumors are counted and lung tumor multiplicity (average number of tumors per lung, including non-tumor bearing animals) is calculated.
  • Results obtained in four different laboratories during the past 8 years have consistently shown significant increases in lung tumor multiplicities in tobacco smoke exposed animals.
  • The counting of surface tumors only may occasionally underestimate total number of lung tumors and thus yield false negatives.
  • Studies with filtered tobacco smoke have suggested that benzo(a)pyrene or tobacco smoke-specific nitrosamines cannot account for lung carcinogenesis in mice; the most likely single agent to cause lung tumors is 1,3-butadiene.
  • While it is easy to detect a 70-100% decrease in lung tumor multiplicity caused by a chemopreventive agent using group sizes of 20-30 animals, the detection of smaller reductions (20-50%) would require group sizes in the hundreds.
  • [MeSH-major] Adenocarcinoma / chemically induced. Adenoma / chemically induced. Disease Models, Animal. Lung Neoplasms / chemically induced. Tobacco Smoke Pollution / adverse effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092725.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA96217; United States / NIEHS NIH HHS / ES / ES05707; United States / NIEHS NIH HHS / ES / ES07499
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  • [Number-of-references] 62
  •  go-up   go-down


78. Kang MS, Lu H, Yasui T, Sharpe A, Warren H, Cahir-McFarland E, Bronson R, Hung SC, Kieff E: Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci U S A; 2005 Jan 18;102(3):820-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBNA1-transgenic lineages had a higher pulmonary adenoma prevalence than did littermate controls (39% versus 7%).
  • However, the adenoma prevalence was not higher in EBNA1-transgenic mice than has been described for FVB mice, and EBNA1 was not expressed in normal pulmonary epithelia or adenomas.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2000 Jul;21(7):1379-89 [10874017.001]
  • [Cites] J Virol. 1999 Dec;73(12):9827-31 [10559294.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28764-73 [10849420.001]
  • [Cites] Virology. 2000 Sep 15;275(1):145-57 [11017796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1865-70 [11172042.001]
  • [Cites] Jpn J Cancer Res. 2001 May;92(5):499-505 [11376558.001]
  • [Cites] J Virol. 2001 Nov;75(22):10582-92 [11602700.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15233-8 [11734622.001]
  • [Cites] FEBS Lett. 2002 Dec 4;532(1-2):135-42 [12459478.001]
  • [Cites] J Virol. 2003 Jun;77(12):6946-56 [12768013.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29987-94 [12783858.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6901-8 [12972608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10989-94 [12947043.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47753-61 [14506283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 [14688409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):141-6 [14691250.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 [6328526.001]
  • [Cites] Nature. 1984 Jul 19-25;310(5974):207-11 [6087149.001]
  • [Cites] Nature. 1985 Feb 28-Mar 6;313(6005):812-5 [2983224.001]
  • [Cites] Cell. 1985 Oct;42(3):859-68 [2996781.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Feb 13;134(3):1260-8 [3004487.001]
  • [Cites] Curr Top Microbiol Immunol. 1986;132:1-8 [3491731.001]
  • [Cites] Mol Cell Biol. 1986 Nov;6(11):3838-46 [3025615.001]
  • [Cites] Cell. 1987 Apr 24;49(2):161-70 [3032447.001]
  • [Cites] J Virol. 1989 Jun;63(6):2657-66 [2542579.001]
  • [Cites] J Exp Med. 1989 Sep 1;170(3):711-26 [2504875.001]
  • [Cites] J Virol. 1990 May;64(5):2369-79 [2157891.001]
  • [Cites] J Virol. 1991 Mar;65(3):1466-78 [1847464.001]
  • [Cites] Jpn J Cancer Res. 1992 Mar;83(3):269-73 [1582889.001]
  • [Cites] J Virol. 1993 Jun;67(6):3418-26 [8388506.001]
  • [Cites] Immunity. 1994 Aug;1(5):415-21 [7533646.001]
  • [Cites] J Virol. 1995 Apr;69(4):2633-6 [7884916.001]
  • [Cites] Nature. 1995 Jun 22;375(6533):685-8 [7540727.001]
  • [Cites] Cell. 1996 Mar 8;84(5):791-800 [8625416.001]
  • [Cites] EMBO J. 1996 Jun 17;15(12):3117-26 [8670812.001]
  • [Cites] Intervirology. 1995;38(3-4):195-205 [8682617.001]
  • [Cites] J Virol. 1996 Dec;70(12):9003-7 [8971032.001]
  • [Cites] Toxicol Pathol. 1996 Nov-Dec;24(6):710-6 [8994298.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8156-61 [9223331.001]
  • [Cites] Virology. 1997 Sep 15;236(1):18-29 [9299613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21 [9356498.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29873-9 [9368061.001]
  • [Cites] Nucleic Acids Res. 1998 Jan 15;26(2):631-7 [9421526.001]
  • [Cites] J Virol. 1998 Nov;72(11):9150-6 [9765461.001]
  • [Cites] J Virol. 1999 Feb;73(2):1630-6 [9882370.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1651-60 [10022853.001]
  • [Cites] J Virol. 1999 Apr;73(4):2974-82 [10074147.001]
  • [Cites] J Virol. 1999 Apr;73(4):3154-61 [10074167.001]
  • [Cites] J Virol. 1999 May;73(5):4385-92 [10196336.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3349-59 [10207059.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22273-7 [10801810.001]
  • (PMID = 15640350.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA047006; United States / NCI NIH HHS / CA / R35 CA047006; United States / NCI NIH HHS / CA / CA47006
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; EC 3.1.3.48 / Antigens, CD45
  • [Other-IDs] NLM/ PMC545574
  •  go-up   go-down


79. Galbiati F, Pettinicchio A, Dragani TA, Manenti G: Allelic effects of mouse Pas1 candidate genes in human lung cancer cell lines. Cancer Lett; 2006 Dec 8;244(2):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic effects of mouse Pas1 candidate genes in human lung cancer cell lines.
  • Four of the six genes constituting the mouse Pulmonary adenoma susceptibility 1 (Pas1) locus haplotype carry amino acid variants: Lrmp, Casc1, Ghiso, and Lmna-rs1.
  • In vitro colony formation assay of human lung cancer cell lines A549 and NCI-H520 transfected with the allelic variants of the four genes revealed allele-specific modulations of colony numbers by Lmna-rs1 and Casc1, but not by Lrmp or Ghiso.
  • [MeSH-major] Adenoma / genetics. Alleles. Genetic Predisposition to Disease. Lung Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis. Carcinoma, Non-Small-Cell Lung / genetics. Cells, Cultured. Colony-Forming Units Assay. Gene Expression Regulation, Neoplastic. Humans. Kidney / metabolism. Male. Membrane Proteins / genetics. Mice. Mice, Inbred A. Mice, Inbred C57BL. Microscopy, Fluorescence. Poly(ADP-ribose) Polymerases / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458428.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Las1 protein, mouse; 0 / Lmna-rs1 protein, mouse; 0 / Lrmp protein, mouse; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


80. Biermasz NR, Smit JW, Pereira AM, Frölich M, Romijn JA, Roelfsema F: Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary; 2007;10(3):237-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Acromegaly / etiology. Adenoma / secretion. Carcinoid Tumor / secretion. Human Growth Hormone / secretion. Lung Neoplasms / secretion. Pancreatic Neoplasms / secretion. Paraneoplastic Endocrine Syndromes / metabolism. Parathyroid Neoplasms / secretion

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7686-90 [2823271.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):281-4 [1619020.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Endocrinology. 1989 Nov;125(5):2710-8 [2507296.001]
  • [Cites] Proc Soc Exp Biol Med. 1990 Mar;193(3):232-5 [2106141.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Mar;32(3):315-21 [2111746.001]
  • [Cites] Endocrinology. 1990 Nov;127(5):2149-56 [2226307.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Sep;73(3):569-76 [1908480.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Endocr Rev. 1992 Aug;13(3):476-98 [1425484.001]
  • [Cites] J Endocrinol Invest. 1993 Jan;16(1):69-81 [8445159.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 2):H1643-56 [8184944.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1277-88 [8083369.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3746-53 [8855833.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):634-7 [9024267.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):611-4; discussion 614-5 [9055303.001]
  • [Cites] Eur J Endocrinol. 1997 Apr;136(4):394-400 [9150699.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Aug;47(2):123-35 [9302383.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):688-92 [9467594.001]
  • [Cites] Eur J Endocrinol. 1998 Feb;138(2):164-9 [9506860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14894-8 [10611309.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):700-12 [11158034.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Mar;280(3):R721-9 [11171650.001]
  • [Cites] Arch Intern Med. 2001 Apr 9;161(7):1010-1 [11295968.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2227-30 [11344231.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):135-40 [11453963.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):3764-73 [11517152.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Dec;281(6):R1975-85 [11705784.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2002 Jun;110(4):188-92 [12058343.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4 [12100081.001]
  • [Cites] Eur J Endocrinol. 2002 Sep;147(3):381-6 [12213676.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):536-9 [12527856.001]
  • [Cites] J Endocrinol Invest. 2003 Feb;26(2):163-9 [12739745.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Jan;286(1):E25-30 [14506078.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):631-2 [15457172.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):453-5 [6432140.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):846-9 [6434585.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2097-108 [6435852.001]
  • [Cites] J Clin Invest. 1985 May;75(5):1584-90 [2860126.001]
  • [Cites] Presse Med. 1985 Dec 7;14(42):2129-34 [2868453.001]
  • [Cites] Am J Physiol. 1986 Apr;250(4 Pt 1):E486-93 [3008572.001]
  • [Cites] Acta Endocrinol (Copenh). 1986 Sep;113(1):23-8 [2876570.001]
  • [Cites] Am J Surg Pathol. 1987 Oct;11(10):810-9 [2889383.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Feb;48(2):243-50 [9579239.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):582-9 [10022420.001]
  • [Cites] Eur J Endocrinol. 1999 Mar;140(3):192-200 [10216513.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1761-2 [10323416.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3162-9 [10487681.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3241-7 [10487694.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] Ir J Med Sci. 2004 Oct-Dec;173(4):215-6 [16323617.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4776-80 [16968791.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):445-50 [2898285.001]
  • (PMID = 17541749.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2045692
  •  go-up   go-down


81. Ozlem Küçük N, Kulak H, Tokmak E, Tar P, Ibiş E, Aras G: Hürthle cell carcinoma: a clinicopathological study of thirteen cases. Nucl Med Commun; 2006 Apr;27(4):377-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distant metastases were detected in only one patient (lung metastasis).
  • A second dose of radioiodine therapy was required in only one patient who had lung metastases and this patient is still being followed up.
  • [MeSH-major] Adenoma, Oxyphilic / radiotherapy. Adenoma, Oxyphilic / surgery. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531925.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals
  •  go-up   go-down


82. Wong HL, Peters U, Hayes RB, Huang WY, Schatzkin A, Bresalier RS, Velie EM, Brody LC: Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced colorectal adenoma risk. Eur J Cancer; 2010 Sep;46(13):2457-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced colorectal adenoma risk.
  • We studied the association of eight APC single nucleotide polymorphisms (SNPs), possibly associated with functional consequences, and previously identified gene-environment (dietary fat intake and hormone replacement therapy (HRT) use) interactions, in relation to advanced colorectal adenoma in 758 cases and 767 sex- and race-matched controls, randomly selected from the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • Cases had at least one verified advanced adenoma of the distal colon; controls, a negative sigmoidoscopy.
  • We did not observe an association between genotypes for any of the eight APC SNPs and advanced distal adenoma risk (P(global gene-based)=0.92).
  • However, the risk for advanced distal adenoma was threefold higher for one rare haplotype (cases: 2.7%; controls: 1.6%) (odds ratio (OR)=3.27; 95% confidence interval (CI)=1.08-9.88).
  • The genetic association between D1822V and advanced distal adenoma was confined to persons consuming a high-fat diet (P(interaction)=0.03).
  • In our large, nested case-control study of advanced distal adenoma and clinically verified adenoma-free controls, we observed no association between specific APC SNPs and advanced adenoma.
  • Fat intake modified the APC D1822V-adenoma association, but further studies are warranted.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Cancer Res. 2008 Jan 15;68(2):358-63 [18199528.001]
  • [Cites] Genomics. 1996 Jun 1;34(2):268-70 [8661068.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):886-9 [11021873.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S [11189683.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):349S-355S [11189687.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1000-4 [11221825.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(4):499-502 [11267860.001]
  • [Cites] Genet Test. 2001 Summer;5(2):141-6 [11551102.001]
  • [Cites] J Med Screen. 2001;8(3):137-44 [11678553.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1799-805 [11734596.001]
  • [Cites] Eur J Cancer. 2010 Mar;46(4):765-81 [20116997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2225-8 [10681434.001]
  • [Cites] Cancer Lett. 2000 Feb 28;149(1-2):203-6 [10737725.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):921-5 [15199111.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):161-3 [15305389.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):769-80 [15510158.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Genetics. 1988 Nov;120(3):849-52 [3224810.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1189-200 [2241098.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 15;84(2):91-8 [1310511.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):884-91 [8388061.001]
  • [Cites] Hum Mol Genet. 1992 Jul;1(4):229-33 [1338904.001]
  • [Cites] Nucleic Acids Res. 1996 Jan 1;24(1):121-4 [8594558.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1028-30 [8612989.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9 [12101109.001]
  • [Cites] Genet Epidemiol. 2002 Oct;23(3):221-33 [12384975.001]
  • [Cites] Am J Hum Genet. 2002 Nov;71(5):1227-34 [12384857.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1023-8 [14578138.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):287-92 [14639617.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):285-9 [9063749.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):79-83 [9288102.001]
  • [Cites] Ann Intern Med. 1998 May 1;128(9):705-12 [9556463.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10722-7 [9724771.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):62-5 [9731533.001]
  • [Cites] Gastroenterology. 1999 Jan;116(1):58-63 [9869603.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):126-32 [15386431.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R171-5 [15743496.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):863-70 [15824157.001]
  • [Cites] Cell Cycle. 2005 Apr;4(4):521-5 [15753653.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1376-80 [15929773.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7516-22 [16103107.001]
  • [Cites] Cancer Causes Control. 2005 Oct;16(8):965-73 [16132805.001]
  • [Cites] Mutat Res. 2005 Dec 30;592(1-2):147-54 [16054167.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21 [16381944.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2789-95 [16393237.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2325-7 [17119068.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Gut. 2007 Mar;56(3):417-25 [16840506.001]
  • [Cites] Breast Cancer Res. 2007;9(2):R27 [17428325.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Am J Clin Nutr. 2007 Jun;85(6):1592-7 [17556698.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):56-64 [18166348.001]
  • (PMID = 20510605.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 HG000120-12
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ NIHMS202303; NLM/ PMC2924917
  •  go-up   go-down


83. Sharon E, Kelly RJ, Szabo E: Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol; 2010;2:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
  • BACKGROUND: Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis.
  • We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine.
  • CASE PRESENTATION: A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy.
  • CONCLUSION: This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy.
  • In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.
  • [MeSH-major] Adenoma, Pleomorphic / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3246-50 [17577021.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):309-19 [18544445.001]
  • [Cites] J Laryngol Otol. 2009 Feb;123(2):250-2 [18405406.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):923-7 [1353853.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):706-13 [12167424.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):724-7 [12907212.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • (PMID = 20504363.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2889991
  •  go-up   go-down


84. Hard GC, Seely JC, Kissling GE, Betz LJ: Spontaneous occurrence of a distinctive renal tubule tumor phenotype in rat carcinogenicity studies conducted by the national toxicology program. Toxicol Pathol; 2008 Apr;36(3):388-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were equally distributed between the sexes, did not metastasize (at least to the lung), and were not associated with chronic progressive nephropathy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2000 Nov;91(11):1096-9 [11092972.001]
  • [Cites] Toxicol Pathol. 2007 Jun;35(4):589-93 [17654399.001]
  • [Cites] Jpn J Cancer Res. 2001 Nov;92(11):1147-9 [11714437.001]
  • [Cites] Toxicol Sci. 2002 Sep;69(1):30-41 [12215658.001]
  • [Cites] Cancer Sci. 2003 Feb;94(2):142-7 [12708488.001]
  • [Cites] Toxicol Pathol. 2004 Mar-Apr;32(2):171-80 [15200155.001]
  • [Cites] Crit Rev Toxicol. 2004 May-Jun;34(3):211-99 [15239388.001]
  • [Cites] Carcinogenesis. 1984 Aug;5(8):1047-50 [6744513.001]
  • [Cites] Toxicol Pathol. 1986;14(1):112-22 [3012758.001]
  • [Cites] J Urol. 1992 Dec;148(6):1932-6 [1433648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11413-6 [7972075.001]
  • [Cites] Toxicol Pathol. 1994 Sep-Oct;22(5):489-96 [7899777.001]
  • [Cites] Nat Genet. 1995 Jan;9(1):70-4 [7704028.001]
  • [Cites] World J Urol. 1995;13(3):153-8 [7550386.001]
  • [Cites] Vet Pathol. 1995 Jul;32(4):419-22 [7483218.001]
  • [Cites] Prog Exp Tumor Res. 1999;35:95-108 [10377754.001]
  • [Cites] Toxicol Pathol. 2005;33(6):641-9 [16207638.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):463-71 [16447066.001]
  • [Cites] Food Chem Toxicol. 2007 Apr;45(4):600-8 [17156907.001]
  • [Cites] Toxicol Pathol. 2007 Feb;35(2):233-41 [17366317.001]
  • [Cites] Toxicol Pathol. 2001 May-Jun;29(3):379-86 [11442024.001]
  • (PMID = 18441261.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / N01ES95435; United States / Intramural NIH HHS / / ZIA ES045003-13; United States / NIEHS NIH HHS / ES / N01-ES-95435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS143842; NLM/ PMC2905801
  •  go-up   go-down


85. Lee WA: Gastric extremely well differentiated adenocarcinoma of gastric phenotype: as a gastric counterpart of adenoma malignum of the uterine cervix. World J Surg Oncol; 2005 May 23;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric extremely well differentiated adenocarcinoma of gastric phenotype: as a gastric counterpart of adenoma malignum of the uterine cervix.
  • On abdominal CT taken after 12 months demonstrated peritoneal carcinomatosis and multiple metastatic foci in the lung.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1031-5 [11014567.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):854-60 [15533229.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):683-92 [12428787.001]
  • (PMID = 15907218.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1180859
  •  go-up   go-down


86. Newman EM, Bouvet M, Borgehi S, Herold DA, Deftos LJ: Causes of hypercalcemia in a population of military veterans in the United States. Endocr Pract; 2006 Sep-Oct;12(5):535-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung carcinoma was the most prevalent malignant condition (in 17 patients or 29% of those with cancer).
  • A single parathyroid adenoma (in 20 of 22 patients who underwent surgical intervention) accounted for the majority of cases of primary hyperparathyroidism.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17002928.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 27YLU75U4W / Phosphorus; 9007-12-9 / Calcitonin; 9NEZ333N27 / Sodium; AYI8EX34EU / Creatinine; FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


87. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol; 2007 Feb;170(2):693-708
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice.
  • Little is known about how the composition of stromal cells within the lung cancer microenvironment varies during tumor progression.
  • We examined by immunohistochemistry each of six different stromal cell populations during the development of chemically induced primary lung cancer in mice.
  • Neutrophils infiltrated the alveoli of tumor-bearing lungs and within the periphery of macroscopic adenomas and adenocarcinomas.
  • Pulmonary macrophages expressed arginase I (subtype M2) but not inducible nitric-oxide synthase in lungs with premalignant lesions, whereas macrophages in carcinoma-bearing lungs expressed inducible nitric-oxide synthase (subtype M1) but not arginase I.
  • Local pulmonary stimuli did not seem responsible for this shift in macrophage activation state because monocytes still residing within the bone marrow adopted these expression patterns before entering the circulation, presumably in response to tumor-derived signals.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2001 Jun;32(3):265-79 [11390008.001]
  • [Cites] J Histochem Cytochem. 2001 Aug;49(8):1061-2 [11457936.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Feb 10;124(3):615-29 [16469706.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):5023-32 [16585599.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1423-33 [11583970.001]
  • [Cites] Toxicology. 2001 Dec 1;169(1):1-15 [11696405.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Cell Prolif. 1999 Dec;32(6):351-61 [10646687.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):509-18 [10666380.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Feb 15;165(4):508-13 [11850344.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6850-6 [12460898.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Nat Rev Immunol. 2003 Jan;3(1):23-35 [12511873.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):186-98 [12539173.001]
  • [Cites] Clin Lung Cancer. 2003 Jul;5(1):46-62 [14596704.001]
  • [Cites] Cell Mol Life Sci. 2003 Nov;60(11):2334-46 [14625680.001]
  • [Cites] Novartis Found Symp. 2004;256:137-45; discussion 146-8, 259-69 [15027487.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3458-64 [15150098.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2053-8 [15164120.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1660-7 [15251154.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5084-8 [15289309.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • [Cites] J Cell Sci. 1966 Sep;1(3):297-310 [4291022.001]
  • [Cites] Int J Cancer. 1967 Jul 15;2(4):326-36 [6055972.001]
  • [Cites] Cancer Res. 1969 May;29(5):994-8 [5781107.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):931-6 [6573537.001]
  • [Cites] Immunology. 1984 Dec;53(4):753-67 [6389324.001]
  • [Cites] J Natl Cancer Inst. 1985 Nov;75(5):963-9 [3863993.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5335-8 [3756882.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):918-31 [2849325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3070-4 [2654935.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Immunol. 1992 Oct 15;149(8):2709-14 [1401910.001]
  • [Cites] N Engl J Med. 1993 Jan 28;328(4):257-65 [8418407.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4848-50 [8069850.001]
  • [Cites] J Exp Med. 1994 Oct 1;180(4):1415-25 [7931074.001]
  • [Cites] Genet Res. 1994 Oct;64(2):99-106 [7813906.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):290-3 [7882795.001]
  • [Cites] Int J Cancer. 1997 Jul 29;72(3):385-8 [9247277.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):E740-7 [9814991.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):57-82 [15765919.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2005-7 [16223785.001]
  • [Cites] J Submicrosc Cytol Pathol. 2005 Aug;37(2):109-204 [16335592.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):197-202 [16337739.001]
  • [Cites] Lung Cancer. 2000 Jan;27(1):27-35 [10672781.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6166-73 [10843666.001]
  • [Cites] Eur Respir J. 2000 Jun;15(6):1087-93 [10885428.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2237-42 [11080091.001]
  • [Cites] Curr Opin Immunol. 2000 Dec;12(6):624-31 [11102764.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Jan;280(1):E75-82 [11120661.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • (PMID = 17255336.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA033497; United States / NCI NIH HHS / CA / R01 CA096133; United States / NCI NIH HHS / CA / CA33497; United States / NCI NIH HHS / CA / CA96133
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinogens; 3IN71E75Z5 / Urethane; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nos2 protein, mouse
  • [Other-IDs] NLM/ PMC1851863
  •  go-up   go-down


88. Hong HH, Houle CD, Ton TV, Sills RC: K-ras mutations in lung tumors and tumors from other organs are consistent with a common mechanism of ethylene oxide tumorigenesis in the B6C3F1 mouse. Toxicol Pathol; 2007 Jan;35(1):81-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras mutations in lung tumors and tumors from other organs are consistent with a common mechanism of ethylene oxide tumorigenesis in the B6C3F1 mouse.
  • In 2-year mouse studies, ethylene oxide (EO) induced lung, Harderian gland (HG), and uterine neoplasms.
  • K-ras mutations were identified in 100% (23/23) of the EO-induced lung neoplasms and 25% (27/108) of the spontaneous lung neoplasms.
  • Codon 12 G to T transversions were common in EO-induced lung neoplasms (21/23) but infrequent in spontaneous lung neoplasms (1/108).
  • These data show a strong predilection for development of K-ras mutations in EO-induced lung, Harderian gland, and uterine neoplasms.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Carcinogens / toxicity. Ethylene Oxide / toxicity. Genes, ras. Lung Neoplasms / genetics. Sebaceous Gland Neoplasms / genetics. Uterine Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYLENE OXIDE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1991 Feb;12(2):299-303 [1995195.001]
  • [Cites] N Engl J Med. 1991 May 16;324(20):1402-7 [2020295.001]
  • [Cites] Mutat Res. 1991 Sep-Oct;250(1-2):483-97 [1719390.001]
  • [Cites] Mutat Res. 1992 Jan;281(1):31-7 [1371589.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4328-34 [1643630.001]
  • [Cites] Chem Biol Interact. 1992 Jun 15;83(1):35-54 [1643667.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):795-801 [8504471.001]
  • [Cites] Mutat Res. 1994 Jan 16;304(2):229-34 [7506366.001]
  • [Cites] Br J Ind Med. 1993 Nov;50(11):971-97 [8280635.001]
  • [Cites] Carcinogenesis. 1994 Nov;15(11):2665-7 [7955123.001]
  • [Cites] Environ Mol Mutagen. 1994;24(3):161-7 [7957119.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;60:1-560 [7869568.001]
  • [Cites] Cancer Lett. 1995 Jun 8;92(2):223-7 [7600534.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1623-8 [7614698.001]
  • [Cites] Jpn J Cancer Res. 1995 Sep;86(9):802-10 [7591956.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Jan;136(1):8-19 [8560484.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):783-9 [9111215.001]
  • [Cites] Mutat Res. 1997 Jul 14;391(3):153-64 [9268040.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):720-3 [9514049.001]
  • [Cites] Eur J Cancer Prev. 1998 Apr;7(2):167-8 [9818781.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):657-62 [10223196.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1787-92 [10469625.001]
  • [Cites] Mutat Res. 1999 Dec 17;431(2):397-415 [10636004.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):27-48 [10686305.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1661-9 [10964097.001]
  • [Cites] Cancer Lett. 2001 Mar 26;164(2):207-12 [11179836.001]
  • [Cites] Mutat Res. 2001 May 31;492(1-2):59-67 [11377244.001]
  • [Cites] Toxicol Pathol. 2001 Jul-Aug;29(4):422-9 [11560247.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;982:177-89 [12562636.001]
  • [Cites] Mutagenesis. 2004 May;19(3):215-22 [15123787.001]
  • [Cites] Pharmacol Rev. 1966 Mar;18(1):805-38 [5325210.001]
  • [Cites] Carcinogenesis. 1990 Feb;11(2):307-12 [2302758.001]
  • [Cites] Mol Carcinog. 1990;3(5):287-95 [2244961.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1241-55 [15809715.001]
  • (PMID = 17325976.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA, Neoplasm; 0 / Disinfectants; JJH7GNN18P / Ethylene Oxide
  • [Other-IDs] NLM/ NIHMS33464; NLM/ PMC2099306
  •  go-up   go-down


89. Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H: Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. Biochem Biophys Res Commun; 2005 Dec 9;338(1):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taking these results into consideration, we hypothesized that the subjects carrying the CYP2A6*4C allele had lower risk of tobacco-related lung cancer.
  • Other mutant alleles reducing the CYP2A6 activity, besides CYP2A6*4C, also reduced the risk of lung cancer in smokers, particularly of squamous-cell carcinoma and small-cell carcinoma, both smoking-related cancers.
  • 8-Methoxypsoralen, an inhibitor of CYP2A6, efficiently prevented the occurrence of adenoma caused by NNK in A/J mice.
  • [MeSH-major] Aryl Hydrocarbon Hydroxylases / genetics. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Mixed Function Oxygenases / genetics. Polymorphism, Genetic. Smoking / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176798.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYP2A6 protein, human; EC 1.- / Mixed Function Oxygenases; EC 1.14.13.- / Cytochrome P-450 CYP2A6; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases
  • [Number-of-references] 37
  •  go-up   go-down


90. Dixon LB, Subar AF, Peters U, Weissfeld JL, Bresalier RS, Risch A, Schatzkin A, Hayes RB: Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma. J Nutr; 2007 Nov;137(11):2443-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma.
  • Our objective was to determine whether adherence to the USDA Food Guide recommendations, the DASH Eating Plan, or a Mediterranean dietary pattern is associated with reduced risk of distal colorectal adenoma.
  • In the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, men and women aged 55-74 y were screened for colorectal cancer by sigmoidoscopy at 10 centers in the U.S.
  • After adjusting for potential confounders, men who most complied with the USDA Food Guide recommendations had a 26% reduced risk of colorectal adenoma compared with men who least complied with the recommendations (OR USDA score >or= 5 vs. <or=2 = 0.74, 95% CI = 0.64-0.85; P-trend < 0.001).
  • Women who most complied with the USDA Food Guide recommendations had an 18% reduced risk for colorectal adenoma, but subgroup analyses revealed protective associations only for current smokers (OR USDA score >or= 5 vs. <or=2 = 0.52, 95% CI = 0.31-0.89; P-trend < 0.01) or normal-weight women (OR USDA score >or= 5 vs. <or=2 = 0.74, 95% CI = 0.55-0.99; P-trend = 0.08).
  • Following the current U.S. dietary recommendations or a Mediterranean dietary pattern is associated with reduced risk of colorectal adenoma, especially in men.
  • [MeSH-major] Adenoma / prevention & control. Colorectal Neoplasms / prevention & control. Diet. Diet, Mediterranean. United States Department of Agriculture

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951483.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


91. DeWitt J, Alsatie M, LeBlanc J, McHenry L, Sherman S: Endoscopic ultrasound-guided fine-needle aspiration of left adrenal gland masses. Endoscopy; 2007 Jan;39(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Our searches resulted in the identification of a series of 38 consecutive patients who underwent EUS for the evaluation of a lung mass (n = 14), a pancreatic mass (n = 14), obstructive jaundice (n = 1), dysphagia (n = 2), an ampullary adenoma (n = 1), celiac block (n = 1), or a left adrenal gland mass (n = 5).
  • Diagnoses after EUS-FNA (the mean number of passes was 3.6) were: metastatic lung cancer (n = 2), esophageal adenocarcinoma (n = 1), melanoma (n = 1), renal cell carcinoma (n = 1), and pancreatic neuroendocrine tumor (n = 1); primary pheochromocytoma (n = 1); benign adrenal tissue (n = 21); and granulomatous inflammation (n = 1).


92. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
PDF icon [Fulltext service] Get downloadable